Ouster (OUST) 10-Q/A 15 Nov 21 2021 Q3 Quarterly report (amended) Financial data

COVER

COVER - shares	9 Months Ended
	Sep. 30, 2021	Nov. 11, 2021
Document Information [Line Items]
Document Type	10-Q/A
Document Quarterly Report	true
Document Period End Date	Sep. 30, 2021
Document Transition Report	false
Entity File Number	001-39463
Entity Registrant Name	Ouster, Inc.
Entity Incorporation, State or Country Code	DE
Entity Tax Identification Number	86-2528989
Entity Address, Address Line One	350 Treat Avenue
Entity Address, City or Town	San Francisco
Entity Address, State or Province	CA
Entity Address, Postal Zip Code	94110
City Area Code	415
Local Phone Number	949-0108
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Entity Filer Category	Non-accelerated Filer
Entity Small Business	true
Entity Emerging Growth Company	true
Entity Ex Transition Period	false
Entity Shell Company	false
Entity Common Stock, Shares Outstanding		171,604,276
Amendment Flag	true
Entity Central Index Key	0001816581
Document Fiscal Year Focus	2021
Document Fiscal Period Focus	Q3
Current Fiscal Year End Date	--12-31
Amendment Description	EXPLANATORY NOTEThis Amendment No. 1 on Form 10-Q/A is being filed solely for the purpose of amending the Section 906 certification (filed herein as Exhibit 32.1 and 32.2) which was originally included with our Quarterly Report on Form 10-Q for the fiscal quarter ended September 30, 2021, filed with the Securities & Exchange Commission on November 12, 2021 (the “Original Form 10-Q”). The certification included with the Original Form 10-Q contained a typographical error. The corrected certification is being filed with this Form 10-Q/A.Items included in the Original Form 10-Q that are not amended by this Form 10-Q/A remain in effect as of the date of the Original Form 10-Q. This amendment does not reflect events occurring after the filing of the Form 10-Q, or modify or update those disclosures that may be affected by subsequent events, and no other changes are being made to any other disclosure contained in the Form 10-Q.
Common stock, $0.0001 par value per share
Document Information [Line Items]
Title of 12(b) Security	Common stock, $0.0001 par value per share
Trading Symbol	OUST
Security Exchange Name	NYSE
Warrants to purchase common stock
Document Information [Line Items]
Title of 12(b) Security	Warrants to purchase common stock
Trading Symbol	OUST WS
Security Exchange Name	NYSE

CONDENSED CONSOLIDATED BALANCE

CONDENSED CONSOLIDATED BALANCE SHEETS - USD ($) $ in Thousands	Sep. 30, 2021	Dec. 31, 2020
Current assets:
Cash and cash equivalents	$ 221,576	$ 11,362
Restricted cash, current	1,008	276
Accounts receivable, net	6,705	2,327
Inventory, net	6,502	4,817
Prepaid expenses and other current assets	6,288	2,441
Total current assets	242,079	21,223
Property and equipment, net	8,411	9,731
Operating lease, right-of-use assets	9,779	11,071
Restricted cash, non-current	1,004	1,004
Other non-current assets	0	3,385
Total assets	261,273	46,414
Current liabilities:
Accounts payable	4,461	6,894
Accrued and other current liabilities	11,438	4,121
Short-term debt	0	7,130
Operating lease liability, current portion	3,057	2,772
Total current liabilities	18,956	20,917
Operating lease liability, long-term portion	9,853	11,908
Warrant liabilities (At September 30, 2021 and December 31, 2020 related party $3,843 and Nil, respectively)	10,979	49,293
Other non-current liabilities	905	978
Total liabilities	40,693	83,096
Commitments and contingencies (Note 7)
Redeemable convertible preferred stock, $0.0001 par value per share; Nil and 131,411,372 shares authorized at September 30, 2021 and December 31, 2020; Nil and 88,434,754 shares issued and outstanding at September 30, 2021 and December 31, 2020, respectively (aggregate liquidation preference of Nil and $41,791 at September 30, 2021 and December 31, 2020, respectively)	0	39,225
Stockholders’ equity / (deficit):
Common stock, $0.0001 par value; 1,000,000,000 and 210,956,516 shares authorized at September 30, 2021 and December 31, 2020, respectively; 161,529,449 and 33,327,294 issued and outstanding at September 30, 2021 and December 31, 2020, respectively	16	0
Preferred stock, $0.0001 par value; 100,000,000 and Nil shares authorized at September 30, 2021 and December 31, 2020, respectively; Nil and Nil issued and outstanding at September 30, 2021 and December 31, 2020, respectively	0	0
Additional paid-in capital	495,576	133,468
Accumulated deficit	(275,012)	(209,375)
Total stockholders’ equity / (deficit)	220,580	(75,907)
Total liabilities, redeemable convertible preferred stock, and stockholders’ equity / (deficit)	$ 261,273	$ 46,414

CONDENSED CONSOLIDATED BALANC_2

CONDENSED CONSOLIDATED BALANCE SHEETS (Parenthetical) - USD ($) $ in Thousands	Sep. 30, 2021	Dec. 31, 2020
Statement of Financial Position [Abstract]
Redeemable convertible preferred stock, par value (in dollars per share)	$ 0.0001	$ 0.0001
Redeemable convertible preferred stock, shares authorized (in shares)	0	131,411,372
Redeemable convertible preferred stock, shares issued (in shares)	0	88,434,754
Redeemable convertible preferred stock, shares outstanding (in shares)	0	88,434,754
Redeemable convertible preferred stock, liquidation preference	$ 0	$ 41,791
Common stock, par value (in dollars per share)	$ 0.0001	$ 0.0001
Common stock, shares authorized (in shares)	1,000,000,000	210,956,516
Common stock, shares issued (in shares)	161,529,449	33,327,294
Common stock, shares outstanding (in shares)	161,529,449	33,327,294
Preferred stock, par value (in dollars per share)	$ 0.0001	$ 0.0001
Preferred stock, shares authorized (in shares)	100,000,000	0
Preferred stock, shares issued (in shares)	0	0
Preferred stock, shares outstanding (in shares)	0	0
Warrant liabilities	$ 10,979	$ 49,293
Related Party
Warrant liabilities	$ 3,843	$ 0

CONDENSED CONSOLIDATED STATEMEN

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2021	Sep. 30, 2020	Sep. 30, 2021	Sep. 30, 2020
Income Statement [Abstract]
Revenue	$ 7,755	$ 5,947	$ 21,726	$ 12,528
Cost of product revenue	5,879	4,884	16,212	12,988
Gross profit (loss)	1,876	1,063	5,514	(460)
Operating expenses:
Research and development	8,390	8,876	19,576	19,028
Sales and marketing	6,737	2,394	14,777	6,305
General and administrative	14,073	4,512	36,177	11,856
Total operating expenses	29,200	15,782	70,530	37,189
Loss from operations	(27,324)	(14,719)	(65,016)	(37,649)
Other (expense) income:
Interest income	165	1	305	24
Interest expense	0	(521)	(504)	(2,196)
Other income (expense), net	14,490	(4,376)	(422)	(9,799)
Total other expense, net	14,655	(4,896)	(621)	(11,971)
Loss before income taxes	(12,669)	(19,615)	(65,637)	(49,620)
Provision for income tax expense	0	0	0	0
Net loss	(12,669)	(19,615)	(65,637)	(49,620)
Comprehensive loss	$ (12,669)	$ (19,615)	$ (65,637)	$ (49,620)
Net loss per common share, basic (in dollars per share)	$ (0.08)	$ (0.97)	$ (0.53)	$ (3.15)
Net loss per common share, diluted (in dollars per share)	$ (0.08)	$ (0.97)	$ (0.53)	$ (3.15)
Weighted-average shares used to compute basic net loss per share (in shares)	156,647,259	20,303,631	123,175,390	15,753,057
Weighted-average shares used to compute diluted net loss per share (in shares)	156,647,259	20,303,631	123,175,390	15,753,057
Product
Income Statement [Abstract]
Revenue	$ 7,755	$ 5,934	$ 21,726	$ 10,524
Cost of product revenue	5,879	4,884	16,212	12,962
Service
Income Statement [Abstract]
Revenue	0	13	0	2,004
Cost of product revenue	$ 0	$ 0	$ 0	$ 26

CONDENSED CONSOLIDATED STATEM_2

CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN REDEEMABLE CONVERTIBLE PREFERRED STOCK AND STOCKHOLDERS’ EQUITY (DEFICIT) - USD ($) $ in Thousands		Total	Redeemable convertible preferred stock		Common Stock		Additional Paid-in- Capital	Notes receivable from stockholders	Accumulated Deficit
Beginning balance (in shares) at Dec. 31, 2019	[1]		4,384,348
Beginning balance at Dec. 31, 2019			$ 40,016
Ending balance (in shares) at Mar. 31, 2020	[1]		4,384,348
Ending balance at Mar. 31, 2020			$ 40,016
Beginning balance (in shares) at Dec. 31, 2019	[1]				7,902,407
Beginning balance at Dec. 31, 2019		$ (100,319)			$ 0		$ 2,320	$ (44)	$ (102,595)
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Issuance of common stock upon exercise of stock options (in shares)	[1]	423
Issuance of common stock upon exercise of stock options		$ 2					2
Vesting of early exercised stock options		12					12
Stock-based compensation expense		175					175
Net loss		(18,693)							(18,693)
Reclassification of a note receivable from a stockholder		44						44
Ending balance (in shares) at Mar. 31, 2020	[1]				7,902,830
Ending balance at Mar. 31, 2020		(118,779)					2,509	0	(121,288)
Beginning balance (in shares) at Dec. 31, 2019	[1]		4,384,348
Beginning balance at Dec. 31, 2019			$ 40,016
Ending balance (in shares) at Sep. 30, 2020	[1]		88,434,754
Ending balance at Sep. 30, 2020			$ 39,225
Beginning balance (in shares) at Dec. 31, 2019	[1]				7,902,407
Beginning balance at Dec. 31, 2019		(100,319)			$ 0		2,320	(44)	(102,595)
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Net loss		(49,620)
Ending balance (in shares) at Sep. 30, 2020	[1]				21,169,429
Ending balance at Sep. 30, 2020		(23,624)			$ 0		128,591	0	(152,215)
Beginning balance (in shares) at Mar. 31, 2020	[1]		4,384,348
Beginning balance at Mar. 31, 2020			$ 40,016
Increase (Decrease) in Temporary Equity [Roll Forward]
Issuance of redeemable convertible preferred stock (in shares)	[1]		43,952,862
Issuance of redeemable convertible preferred stock			$ 18,330
Conversion of redeemable convertible preferred stock to common stock (in shares)	[1]		(4,384,348)
Conversion of redeemable convertible preferred stock to common stock			$ (40,016)
Ending balance (in shares) at Jun. 30, 2020	[1]		43,952,862
Ending balance at Jun. 30, 2020			$ 18,330
Beginning balance (in shares) at Mar. 31, 2020	[1]				7,902,830
Beginning balance at Mar. 31, 2020		(118,779)					2,509	0	(121,288)
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Conversion of redeemable convertible preferred stock to common stock (in shares)	[1]				4,384,348
Conversion of redeemable convertible preferred stock to common stock		40,016			$ 0		40,016
Vesting of early exercised stock options		12					12
Stock-based compensation expense		460					460
Net loss		(11,312)							(11,312)
Conversion of convertible notes to common stock (in shares)	[1]				7,201,911
Conversion of convertible notes to common stock		78,311					78,311
Ending balance (in shares) at Jun. 30, 2020	[1]				19,489,089
Ending balance at Jun. 30, 2020		(11,292)			$ 0		121,308	0	(132,600)
Increase (Decrease) in Temporary Equity [Roll Forward]
Issuance of redeemable convertible preferred stock (in shares)	[1]		44,481,892
Issuance of redeemable convertible preferred stock			$ 20,895
Ending balance (in shares) at Sep. 30, 2020	[1]		88,434,754
Ending balance at Sep. 30, 2020			$ 39,225
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Issuance of common stock upon exercise of stock options (in shares)	[1]				63,076
Issuance of common stock upon exercise of stock options		7					7
Vesting of early exercised stock options		12					12
Stock-based compensation expense		7,256					7,256
Net loss		(19,615)							(19,615)
Issuance of common stock upon exercise of restricted stock awards (in shares)	[1]				1,617,264
Issuance of common stock upon exercise of restricted stock awards		8					8
Ending balance (in shares) at Sep. 30, 2020	[1]				21,169,429
Ending balance at Sep. 30, 2020		$ (23,624)			$ 0		128,591	0	(152,215)
Beginning balance (in shares) at Dec. 31, 2020		88,434,754	88,434,754	[1]
Beginning balance at Dec. 31, 2020		$ 39,225	$ 39,225
Increase (Decrease) in Temporary Equity [Roll Forward]
Issuance of redeemable convertible preferred stock (in shares)	[1]		4,232,947
Issuance of redeemable convertible preferred stock			$ 58,097
Conversion of redeemable convertible preferred stock to common stock (in shares)	[1]		(92,667,701)
Conversion of redeemable convertible preferred stock to common stock			$ (97,322)
Ending balance (in shares) at Mar. 31, 2021	[1]		0
Ending balance at Mar. 31, 2021			$ 0
Beginning balance (in shares) at Dec. 31, 2020		33,327,294			33,327,294	[1]
Beginning balance at Dec. 31, 2020		$ (75,907)			$ 0		133,468	0	(209,375)
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Issuance of common stock upon exercise of stock options (in shares)	[1]				727,114
Issuance of common stock upon exercise of stock options		190			$ 1		189
Repurchase of common stock (shares)	[1]				(220,561)
Repurchase of common stock		(43)					(43)
Conversion of redeemable convertible preferred stock to common stock (in shares)	[1]				92,667,701
Conversion of redeemable convertible preferred stock to common stock		97,334			$ 12		97,322
Issuance of common stock upon merger and private offering, net of acquired private placement warrants of $19,377 (in shares)	[1]				34,947,657
Issuance of common stock upon merger and private offering, net of acquired private placement warrants of $19,377		272,064			$ 3		272,061
Offering costs in connection with the merger		(26,620)					(26,620)
Vesting of early exercised stock options		438					438
Stock-based compensation expense		5,256					5,256
Net loss		(20,957)							(20,957)
Ending balance (in shares) at Mar. 31, 2021	[1]				161,449,205
Ending balance at Mar. 31, 2021		$ 251,755			$ 16		482,071	0	(230,332)
Beginning balance (in shares) at Dec. 31, 2020		88,434,754	88,434,754	[1]
Beginning balance at Dec. 31, 2020		$ 39,225	$ 39,225
Ending balance (in shares) at Sep. 30, 2021		0	0	[1]
Ending balance at Sep. 30, 2021		$ 0	$ 0
Beginning balance (in shares) at Dec. 31, 2020		33,327,294			33,327,294	[1]
Beginning balance at Dec. 31, 2020		$ (75,907)			$ 0		133,468	0	(209,375)
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Issuance of common stock upon exercise of stock options (in shares)		913,279
Net loss		$ (65,637)
Ending balance (in shares) at Sep. 30, 2021		161,529,449			161,529,449	[1]
Ending balance at Sep. 30, 2021		$ 220,580			$ 16		495,576	0	(275,012)
Beginning balance (in shares) at Mar. 31, 2021	[1]		0
Beginning balance at Mar. 31, 2021			$ 0
Ending balance (in shares) at Jun. 30, 2021	[1]		0
Ending balance at Jun. 30, 2021			$ 0
Beginning balance (in shares) at Mar. 31, 2021	[1]				161,449,205
Beginning balance at Mar. 31, 2021		251,755			$ 16		482,071	0	(230,332)
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Vesting of early exercised stock options		104					104
Stock-based compensation expense		6,154					6,154
Net loss		(32,011)							(32,011)
Ending balance (in shares) at Jun. 30, 2021	[1]				161,449,205
Ending balance at Jun. 30, 2021		$ 226,002			$ 16		488,329	0	(262,343)
Ending balance (in shares) at Sep. 30, 2021		0	0	[1]
Ending balance at Sep. 30, 2021		$ 0	$ 0
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Issuance of common stock upon exercise of stock options (in shares)	[1]				186,165
Issuance of common stock upon exercise of stock options		35			$ 0		35
Cancellation of previously issued awards (in shares)					(105,921)
Vesting of early exercised stock options		65					65
Stock-based compensation expense		7,147					7,147
Net loss		$ (12,669)							(12,669)
Ending balance (in shares) at Sep. 30, 2021		161,529,449			161,529,449	[1]
Ending balance at Sep. 30, 2021		$ 220,580			$ 16		$ 495,576	$ 0	$ (275,012)
[1]	The shares of the Company’s common and redeemable convertible preferred stock, prior to the Merger (as defined in Note 1), have been retroactively restated as shares reflecting the exchange ratio of approximately 0.703 established in the Merger as described in Note 1.

CONDENSED CONSOLIDATED STATEM_3

CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN REDEEMABLE CONVERTIBLE PREFERRED STOCK AND STOCKHOLDERS’ EQUITY (DEFICIT) (Parenthetical) $ in Thousands	3 Months Ended	9 Months Ended
	Mar. 31, 2021USD ($)	Sep. 30, 2021USD ($)	Sep. 30, 2020USD ($)
Statement of Stockholders' Equity [Abstract]
Private placement warrants acquired as part of the merger	$ 19,377	$ 19,377	$ 0
Share exchange ratio		0.703	0.703

CONDENSED CONSOLIDATED STATEM_4

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS - USD ($) $ in Thousands	9 Months Ended
	Sep. 30, 2021	Sep. 30, 2020
CASH FLOWS FROM OPERATING ACTIVITIES
Net loss	$ (65,637)	$ (49,620)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization	3,428	2,705
Stock-based compensation	18,557	7,891
Change in right-of-use asset	1,292	1,388
Interest expense on notes and convertible debt	36	840
Amortization of debt issuance costs and debt discount	250	335
Change in fair value of warrant liabilities	406	6,097
Change in fair value of derivative liability	0	5,308
Gain on extinguishment of tranche right liability	0	(1,610)
Inventory write down	866	1,156
Changes in operating assets and liabilities:
Accounts receivable	(4,378)	(2,023)
Inventory	(2,551)	(4,064)
Prepaid expenses and other assets	42	21
Accounts payable	(2,707)	(625)
Accrued and other liabilities	7,060	(2,001)
Operating lease liability	(1,770)	(429)
Net cash used in operating activities	(45,106)	(34,631)
CASH FLOWS FROM INVESTING ACTIVITIES
Purchases of property and equipment	(1,774)	(2,394)
Net cash used in investing activities	(1,774)	(2,394)
Net Cash Provided by (Used in) Financing Activities [Abstract]
Proceeds from the merger and private offering	291,454	0
Payment of offering costs	(27,124)	0
Repayment of debt	(7,000)	(3,000)
Proceeds from issuance of promissory notes to related parties	5,000	0
Repayment of promissory notes to related parties	(5,000)	0
Repurchase of common stock	(43)	0
Proceeds from exercise of stock options	539	9
Issuance of common stock upon exercise of restricted stock awards	0	8
Proceeds from issuance of Series B redeemable convertible preferred stock, net of issuance cost of $265	0	41,526
Net cash provided by financing activities	257,826	38,543
Net increase in cash, cash equivalents and restricted cash	210,946	1,518
Cash, cash equivalents and restricted cash at beginning of period	12,642	18,405
Cash, cash equivalents and restricted cash at end of period	223,588	19,923
SUPPLEMENTAL DISCLOSURES OF OPERATING ACTIVITIES:
Cash paid for interest	635	1,020
SUPPLEMENTAL DISCLOSURES OF NON-CASH INVESTING AND FINANCING INFORMATION:
Property and equipment purchases included in accounts payable and accrued liabilities	334	12
Private placement warrants acquired as part of the merger	19,377	0
Issuance of redeemable convertible preferred stock upon exercise of warrants	58,097	0
Conversion of redeemable convertible preferred stock to common stock	97,322	40,016
Right-of-use assets obtained in exchange for operating lease liability	0	6,234
Issuance of common stock pursuant to the conversion of convertible notes and accrued interest	$ 0	$ 78,311

CONDENSED CONSOLIDATED STATEM_5

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (Parenthetical) $ in Thousands	9 Months Ended
	Sep. 30, 2020USD ($)
Statement of Cash Flows [Abstract]
Issuance cost	$ 265

Description of Business and Bas

Description of Business and Basis of Presentation	9 Months Ended
	Sep. 30, 2021
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Description of Business and Basis of Presentation	Description of Business and Basis of Presentation Description of Business Ouster, Inc. was incorporated in the state of Delaware on June 4, 2020. The Company’s operating subsidiary, Ouster Technologies, Inc. (“OTI” and prior to the Merger (as defined below), named Ouster, Inc.), was incorporated in the state of Delaware on June 30, 2015. The Company is a leading provider of high-resolution digital lidar sensors that offer advanced 3D vision to machinery, vehicles, robots, and fixed infrastructure assets, allowing each to understand and visualize the surrounding world and ultimately enabling safe operation and ubiquitous autonomy. Unless the context otherwise requires, references in this subsection to “the Company” refer to the business and operations of OTI (formerly known as Ouster, Inc.) and its consolidated subsidiaries prior to the Merger (as defined below) and to Ouster, Inc. (formerly known as Colonnade Acquisition Corp.) and its consolidated subsidiaries following the consummation of the Merger. Colonnade Acquisition Corp. (“CLA”), the Company’s predecessor, was originally a blank check company incorporated as a Cayman Islands exempted company on June 4, 2020. The Company was formed for the purpose of effecting a merger, share exchange, asset acquisition, share purchase, reorganization or similar business combination with one or more businesses. On March 11, 2021, CLA consummated a merger with the Company pursuant to an Agreement and Plan of Merger (the “Merger Agreement”) dated as of December 21, 2020, details of which are included below. Basis of Presentation and Principles of Consolidation The unaudited condensed consolidated financial statements include the accounts of the Company and its subsidiaries (all of which are wholly owned) and have been prepared in conformity with U.S. generally accepted accounting principles (“US GAAP”) applicable to interim periods. The functional currency for the Company is the United States dollar. All intercompany balances and transactions have been eliminated in consolidation. The unaudited condensed consolidated financial statements include all adjustments (consisting of only normal recurring adjustments) necessary for a fair statement of the results of operations for the periods shown. The unaudited condensed consolidated financial statements should be read in conjunction with the Company’s audited consolidated financial statements as of and for the year ended December 31, 2020 and the notes related thereto, included as Exhibit 99.1 to the Form 8-K filed with the Securities and Exchange Commission (“SEC”) on March 15, 2021, as amended on July 12, 2021. The year-end condensed balance sheet data was derived from audited financial statements, but does not include all disclosures required by US GAAP. Certain information and note disclosures normally included in the audited financial statements prepared in accordance with US GAAP have been condensed or omitted from this report, as is permitted by such rules and regulations. The results of operations for any interim period are not necessarily indicative of the results to be expected for the year ending December 31, 2021 or for any other future years or interim periods. Impact of the COVID-19 Pandemic The Company has been actively monitoring the ongoing COVID-19 pandemic situation and its impact on the Company’s business. In response to the pandemic, numerous state and local jurisdictions have imposed “shelter-in-place” orders, quarantines and other restrictions. In the United States, governmental authorities have, at times, recommended, and in certain cases required, that elective, specialty and other procedures and appointments, be suspended or canceled. In the United States, COVID-19 restrictions continue to vary state by state as the measures depend greatly on the political landscape and the resurgence of new cases. In California, where the Company’s headquarters are located, face coverings indoors are still recommended regardless of vaccination status, and some counties continue to have mask mandates. Such orders or restrictions resulted in reduced operations at the Company’s headquarters (including its manufacturing facility), work stoppages, slowdowns and delays, travel restrictions and cancellation of events and have restricted the efforts of the Company’s sales representatives, thereby significantly and negatively impacting the Company’s operations. The full extent to which the COVID-19 pandemic will directly or indirectly impact our business, results of operations and financial condition, including sales, expenses, reserves and allowances, manufacturing, research and development costs and employee-related amounts, will depend on future developments that are highly uncertain, including as a result of new information that may emerge concerning COVID-19, including variants, the progression and effectiveness of vaccination roll-outs, vaccination hesitancy, and the actions taken to contain it or treat COVID-19, as well as the economic impact on local, regional, national and international customers and markets. The situation surrounding COVID-19 remains fluid and the potential for a material impact on the Company increases the longer the virus impacts the level of economic activity in the United States and globally. Given the ongoing evolution of the COVID-19 and the global responses to curb its spread, the Company is not able to estimate the effects of the COVID-19 on its results of operations, financial condition, or liquidity for the year ending December 31, 2021 and beyond. Liquidity The accompanying unaudited condensed consolidated financial statements have been prepared on a going concern basis. The Company has experienced recurring losses from operations, and negative cash flows from operations. As of September 30, 2021, the Company had an accumulated deficit of approximately $275.0 million. The Company has historically financed its operations primarily through the Merger and related transactions, the sale of convertible notes, equity securities, proceeds from debt and, to a lesser extent, cash received from sales. Management expects significant operating losses and negative cash flows from operations to continue for the foreseeable future. The Company expects to continue investing in product development and sales and marketing activities. The long-term continuation of the Company’s business plan is dependent upon the generation of sufficient revenues from its products to offset expenses. In the event that the Company does not generate sufficient cash flows from operations and is unable to obtain funding, the Company will be forced to delay, reduce, or eliminate some or all of its discretionary spending, which could adversely affect the Company’s business prospects, ability to meet long-term liquidity needs or ability to continue operations. The Company has concluded that its cash and cash equivalents as of September 30, 2021 are sufficient for the Company to continue as a going concern for at least one year from the date these unaudited condensed consolidated financial statements are available for issuance. Merger Agreement with Colonnade Acquisition Corp. and Beam Merger Sub, Inc. On December 21, 2020, OTI entered into the Merger Agreement with CLA and Beam Merger Sub, Inc. (“Merger Sub”), a Delaware corporation and subsidiary of CLA. OTI’s board of directors unanimously approved OTI’s entry into the Merger Agreement, and on March 11, 2021, the transactions contemplated by the Merger Agreement were consummated. Pursuant to the terms of the Merger Agreement, (i) CLA domesticated as a corporation incorporated under the laws of the State of Delaware and changed its name to “Ouster, Inc.” and (ii) Merger Sub merged with and into OTI (such transactions contemplated by the Merger Agreement, the “Merger”), with OTI surviving the Merger. As a result of the Merger, among other things, (1) each of the then issued and outstanding 5,000,000 CLA Class B ordinary shares, par value $0.0001 per share, of CLA (the “CLA Class B ordinary shares”) converted automatically, on a one-for-one basis, into a CLA Class A ordinary share (as defined below), (2) immediately following the conversion described in clause (1), each of the then issued and outstanding 25,000,000 Class A ordinary shares, par value $0.0001 per share, of CLA (the “CLA Class A ordinary shares”), converted automatically, on a one-for-one basis, into a share of common stock, par value $0.0001 per share, of Ouster (the “Ouster common stock”), (3) each of the then issued and outstanding 10,000,000 redeemable warrants of CLA (the “CLA warrants”) converted automatically into a redeemable warrant to purchase one share of Ouster common stock (the “Public warrants”) pursuant to the Warrant Agreement, dated August 20, 2020 (the “Warrant Agreement”), between CLA and Continental Stock Transfer & Trust Company (“Continental”), as warrant agent, and (4) each of the then issued and outstanding units of CLA that had not been previously separated into the underlying CLA Class A ordinary shares and underlying CLA warrants upon the request of the holder thereof (the “CLA units”), were cancelled and entitled the holder thereof to one share of Ouster common stock and one-half of one Public warrant, and (5) each of the then issued and outstanding 6,000,000 private placement warrants of CLA (the “Private Placement warrants”) converted automatically into a Public warrant pursuant to the Warrant Agreement. No fractional Public warrants were issued upon separation of the CLA units. Immediately prior to the effective time of the Merger, (1) each share of OTI’s Series B Preferred Stock, par value $0.00001 per share (the “OTI Preferred Stock”), converted into one share of common stock, par value $0.00001 per share, of OTI (the “OTI common stock” and, together with OTI Preferred Stock, the “OTI Capital Stock”) (such conversion, the “OTI Preferred Conversion”) and (2) all of the outstanding warrants to purchase shares of OTI Capital Stock were exercised in full or terminated in accordance with their respective terms (the “OTI Warrant Settlement”). As a result of and upon the closing of the Merger, among other things, all shares of OTI Capital Stock (after giving effect to the OTI Warrant Settlement) outstanding immediately prior to the closing of the Merger together with shares of OTI common stock reserved in respect of options to purchase shares of OTI common stock and restricted shares of OTI common stock (together, the “OTI Awards”) outstanding immediately prior to the closing of the Merger that were converted into awards based on Ouster common stock, were cancelled in exchange for the right to receive, or the reservation of, an aggregate of 150,000,000 shares of Ouster common stock (at a deemed value of $10.00 per share), which, in the case of OTI Awards, were shares underlying awards based on Ouster common stock, representing a fully-diluted pre-transaction. Upon closing of the Merger, the Company received gross proceeds of $299.9 million from the Merger and private offering, offset by $8.5 million of pre-merger costs relating to CLA and offerings costs of $26.6 million. The Merger was accounted for as a reverse recapitalization under US GAAP. Under this method of accounting, CLA is treated as the “acquired” company for financial reporting purposes. This determination is primarily based on OTI stockholders comprising a relative majority of the voting power of the Company and having the ability to nominate the members of the board of directors of the Company after the Merger, OTI’s operations prior to the Merger comprising the only ongoing operations of the Company following the Merger, and OTI’s senior management prior to the Merger comprising a majority of the senior management of the Company following the Merger. Accordingly, for accounting purposes, the financial statements of the Company represent a continuation of the financial statements of OTI with the Merger being treated as the equivalent of OTI issuing stock for the net assets of CLA, accompanied by a recapitalization whereby no goodwill or other intangible assets are recorded. Transactions and balances prior to the Merger are those of OTI. The shares and net loss per share available to holders of OTI’s common stock prior to the Merger have been retroactively restated as shares reflecting the exchange ratio established in the Merger Agreement. PIPE Investment

Summary of Significant Accounti

Summary of Significant Accounting Policies	9 Months Ended
	Sep. 30, 2021
Accounting Policies [Abstract]
Summary of Significant Accounting Policies	Summary of Significant Accounting Policies During the nine months ended September 30, 2021, there were no significant changes to the Company’s significant accounting policies. Recently Issued Accounting Pronouncements Based on our public float as of June 30, 2021, we expect to become a large accelerated filer, and lose emerging growth company status, as of December 31, 2021. As of December 31, 2021, we will be required to adopt new or revised accounting standards when they are applicable to public companies that are not emerging growth companies. In June 2016, the FASB issued ASU 2016-13, Financial Instruments—Credit Losses (Topic 326), to introduce a new impairment model for recognizing credit losses on financial instruments based on an estimate of current expected credit losses (“ECL”). Under the new model, an entity is required to estimate ECL on available-for-sale (AFS) debt securities only when the fair value is below the amortized cost of the asset and is no longer based on an impairment being “other-than-temporary”. The new model also requires the impairment calculation on an individual security level and requires an entity to use the present value of cash flows when estimating the ECL. The credit-related losses are required to be recognized through earnings and non-credit related losses are reported in other comprehensive income. The Company will adopt ASC 2016-13 for the December 31, 2021 annual period, with a modified retrospective application to all outstanding instruments and a cumulative effect adjustment recorded to opening retained earnings as of January 1, 2021. The Company does not believe the adoption of this new guidance will have a material impact on its consolidated financial statements. In August 2018, the FASB issued ASU 2018-15, Intangibles-Goodwill and Other-Internal-Use Software (Subtopic 350-40): Customer’s Accounting for Implementation Costs Incurred in a Cloud Computing Arrangement That Is a Service Contract, which aligns the requirements for capitalizing implementation costs incurred in a cloud computing arrangement that is a service contract with the requirements for capitalizing implementation costs incurred to develop or obtain internal-use software. The Company will adopt ASC 2018-15 for the December 31, 2021 annual period. The Company does not believe the adoption of this new guidance will have a material impact on its consolidated financial statements. In August 2020, the FASB issued ASU No. 2020-06, Debt – Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging – Contracts in Entity’s Own Equity (Subtopic 815-40): Accounting for Convertible Instruments and Contracts in an Entity’s Own Equity (“ASU 2020-06). ASU 2020-06 simplifies the accounting for convertible debt and convertible preferred stock by removing the requirements to separately present certain conversion features in equity. In addition, the amendments in the ASU also simplify the guidance in ASC 815-40, Derivatives and Hedging: Contracts in Entity’s Own Equity, by removing certain criteria that must be satisfied in order to classify a contract as equity, which is expected to decrease the number of freestanding instruments and embedded derivatives accounted for as assets or liabilities. Finally, the amendments revise the guidance on calculating earnings per share, requiring use of the if-converted method for all convertible instruments and rescinding an entity’s ability to rebut the presumption of share settlement for instruments that may be settled in cash or other assets. The new standard is effective for the Company for annual periods beginning December 15, 2021. The Company is currently evaluating the impact of the adoption of this ASU on the Company’s condensed consolidated financial statements. In October 2021, the FASB issued ASU 2018-08, Business Combinations (Topic 805): Accounting for Contract Assets and Contract Liabilities from Contracts with Customers, which amends ASC 805 to add contract assets and contract liabilities to the list of exceptions to the recognition and measurement principles that apply to business combinations and to require that an entity (acquirer) recognize and measure contract assets and contract liabilities acquired in a business combination in accordance with Topic 606. The amendments in this ASU are effective for fiscal years beginning after December 15, 2022, including interim periods within those fiscal years and should be applied prospectively to business combinations occurring on or after the effective date of the amendments. Early adoption of the amendments is permitted, including adoption in an interim period. The Company is currently evaluating the impact of the adoption of this ASU on the Company’s condensed consolidated financial statements. There have been no other newly issued or newly applicable accounting pronouncements that do not require adoption until a future date that have had, or are expected to have, a significant impact on the Company’s condensed consolidated financial statements. Concentrations of credit risk Financial instruments that potentially subject the Company to credit risk consist primarily of cash, cash equivalents, and restricted cash, and accounts receivable. Cash, cash equivalents and restricted cash are deposited with federally insured commercial banks in the United States and at times cash balances may be in excess of federal insurance limits. The Company generally does not require collateral or other security deposits for accounts receivable. To reduce credit risk, the Company considers customer creditworthiness, past transaction history with the customer, current economic industry trends, and changes in customer payment terms when determining the collectability of specific customer accounts. Past due balances over 90 days and other higher risk amounts are reviewed individually for collectability. Based on management’s assessment, the Company provides for estimated uncollectible amounts through a charge to earnings and a credit to valuation allowance. Balances that remain outstanding after the Company has used reasonable collection efforts are written off through a charge to the valuation allowance and a credit to accounts receivable. Accounts receivable from the Company’s major customers representing 10% or more of total accounts receivable was as follows: September 30, December 31, Customer A * 13 % Customer B * 23 % Customer C 14 % * * Customer accounted for less than 10% of total accounts receivable as of such date. Revenue from the Company’s major customers representing 10% or more of total revenue was as follows: Three Months Ended September 30, Nine Months Ended September 30, 2021 2020 2021 2020 Customer D * * 10 % * Customer E * * * 16 % * Customer accounted for less than 10% of total revenue in the period. Concentrations of supplier risk Purchases from the Company’s major suppliers representing 10% or more of total purchases were as follows: Three Months Ended September 30, Nine Months Ended September 30, 2021 2020 2021 2020 Supplier A 19 % 19 % 17 % 15 %

Fair Value of Financial Instrum

Fair Value of Financial Instruments	9 Months Ended
	Sep. 30, 2021
Fair Value Disclosures [Abstract]
Fair Value of Financial Instruments	Fair Value of Financial Instruments The Company applies the fair value measurement accounting standard whenever other accounting pronouncements require or permit fair value measurements. Fair value is defined in the accounting standard as the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. The fair value hierarchy is based on inputs to valuation techniques that are used to measure fair value that are either observable or unobservable. Observable inputs reflect assumptions market participants would use in pricing an asset or liability based on market data obtained from independent sources, while unobservable inputs reflect a reporting entity’s pricing based upon their own market assumptions. The fair value hierarchy consists of the following three levels: • Level 1 - Quoted prices for identical instruments in active markets. • Level 2 - Quoted prices for similar instruments in active markets; quoted prices for identical or similar instruments in markets that are not active; and model-derived valuations whose inputs are observable or whose significant value drivers are observable. • Level 3 - Instruments whose significant value drivers are unobservable. On September 30, 2021, the Company’s Level 3 liabilities consisted of the Private Placement warrant liability. The determination of the fair value of warrant liability is discussed in Note 6 . On December 31, 2020, the Company’s Level 3 liabilities consisted of the redeemable convertible preferred stock warrant liability. The determination of the fair value of warrant liability is discussed in Note 6 . The following table provides information by level for the Company’s assets and liabilities that were measured at fair value on a recurring basis (in thousands): September 30, 2021 Level 1 Level 2 Level 3 Total Assets Money market funds $ 219,276 $ — $ — $ 219,276 Total financial assets $ 219,276 $ — $ — $ 219,276 Liabilities Warrant liabilities $ — $ — $ 10,979 $ 10,979 Total financial liabilities $ — $ — $ 10,979 $ 10,979 December 31, 2020 Level 1 Level 2 Level 3 Total Assets Money market funds $ 10,493 $ — $ — $ 10,493 Total financial assets $ 10,493 $ — $ — $ 10,493 Liabilities Warrant liabilities $ — $ — $ 49,293 $ 49,293 Total financial liabilities $ — $ — $ 49,293 $ 49,293 Money market funds are included within Level 1 of the fair value hierarchy because they are valued using quoted market prices. The fair value of the redeemable convertible preferred stock warrant, redeemable convertible preferred stock tranche and Private Placement warrant liabilities is based on significant unobservable inputs, which represent Level 3 measurements within the fair value hierarchy. In determining the fair value of the warrant liabilities, the Company used the Black-Scholes option pricing model to estimate the fair value using unobservable inputs including the expected term, expected volatility, risk-free interest rate and dividend yield (see Note 6 ). The following table presents a summary of the changes in the fair value of the Company’s Level 3 financial instruments (in thousands): Redeemable Redeemable Private Placement Warrant Liability Derivative Fair value as of January 1, 2020 $ (162) $ — $ — $ — Change in the fair value included in other income (expense), net (6,097) — — (5,308) Recognition of preferred stock warrant and tranche liability upon issuance (691) (1,610) — — Extinguishment of derivative liability upon conversion of convertible notes — — — 5,308 Fair value as of Settlement of redeemable convertible preferred stock tranche liability due to the issuance of Series B redeemable convertible preferred stock — 1,610 — — Fair value as of September 30, 2020 $ (6,950) $ — $ — $ — Fair value as of January 1, 2021 $ (49,293) $ — $ — $ — Private placement warrant liability acquired as part of the Merger — — (19,377) — Change in the fair value included in other income (expense), net (8,804) — 8,398 — Issuance of preferred stock upon exercise of warrants 58,097 — — — Fair value as of September 30, 2021 $ — $ — $ (10,979) $ — Disclosure of Fair Values

Balance Sheet Components

Balance Sheet Components	9 Months Ended
	Sep. 30, 2021
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Balance Sheet Components	Balance Sheet Components Cash and Cash Equivalents The Company’s cash and cash equivalents consist of the following (in thousands): September 30, December 31, Cash $ 2,300 $ 869 Cash equivalents: Money market funds (1) 219,276 10,493 Total cash and cash equivalents $ 221,576 $ 11,362 (1) The Company maintains a cash sweep account which is included in money market funds as of September 30, 2021. Cash is invested in the short-term money market funds, which is a cash sweep for uninvested cash that earns interest. Restricted Cash Restricted cash consists of certificates of deposit held by a bank as security for outstanding letters of credit. The Company had a restricted cash balance of $2.0 million and $1.3 million as of September 30, 2021 and December 31, 2020, respectively, which has been excluded from the Company’s cash and cash equivalents balances. The Company presented $1.0 million and $0.3 million of the total amount of restricted cash within current assets on the condensed consolidated balance sheets as of September 30, 2021 and December 31, 2020, respectively. The remaining restricted cash balance of $1.0 million and $1.0 million is included in non-current assets on the condensed consolidated balance sheets as of September 30, 2021 and December 31, 2020, respectively. Reconciliation of cash, cash equivalents and restricted cash as shown in the condensed consolidated statement of cash flows to the respective accounts within the condensed consolidated balance sheet is as follows (in thousands): September 30, September 30, Cash and cash equivalents $ 221,576 $ 18,367 Restricted cash, current 1,008 276 Restricted cash, non-current 1,004 1,280 Total cash, cash equivalents and restricted cash $ 223,588 $ 19,923 Inventory Inventory, consisting of material, direct and indirect labor, and manufacturing overhead, consists of the following (in thousands): September 30, December 31, Raw materials $ 2,269 $ 1,376 Work in process 2,165 1,249 Finished goods 2,068 2,192 Total inventory $ 6,502 $ 4,817 Total inventory balance as of September 30, 2021 and December 31, 2020 includes a write down of $2.6 million and $2.7 million, respectively, for obsolete, scrap, or returned inventory. During the three months ended September 30, 2021 and 2020, $0.7 million and $0 million of inventory write offs were charged to cost of revenue. During the nine months ended September 30, 2021 and 2020, respectively, $0.9 million and $1.2 million of inventory write offs were charged to cost of revenue. Prepaid expenses and other current assets Prepaid expenses and other current assets consist of the following (in thousands): September 30, December 31, Prepaid insurance $ 3,473 $ 206 Prepaid expenses 1,583 694 Receivable from contract manufacturer 53 1,521 Security deposit 1,179 20 Total prepaid and other current assets $ 6,288 $ 2,441 Accrued and Other Current Liabilities Accrued and other current liabilities consist of the following (in thousands): September 30, December 31, Customer deposits $ 48 $ 71 Accrued compensation 2,640 1,618 Uninvoiced receipts 7,726 1,947 Other 1,024 485 Total accrued and other current liabilities $ 11,438 $ 4,121

Debt

Debt	9 Months Ended
	Sep. 30, 2021
Debt Disclosure [Abstract]
Debt	Debt Runway Growth Loan Agreement On November 27, 2018, the Company entered into a Loan and Security Agreement with Runway Growth Credit Fund Inc. (“Runway Loan and Security Agreement”). The Runway Loan and Security Agreement provided for loans in an aggregate principal amount up to $10.0 million with a loan maturity date of November 15, 2021. The loan carried an interest rate equal to LIBOR plus 8.5%, unless LIBOR becomes no longer attainable or ceases to fairly reflect the costs of the lender, in which case the applicable interest rate shall be Prime Rate plus 6.0%. In an event of default, annual interest is increased by 5.0% above the otherwise applicable rate. The loan’s annual effective interest rate was approximately 16.4% for each of the nine months ended September 30, 2021 and 2020. In conjunction with the Runway Loan and Security Agreement, the Company issued a warrant to purchase 35,348 shares of Series A redeemable convertible preferred stock (the “Series A Preferred Stock”) of OTI (4.0% of original principal amount of $10.0 million, divided by the exercise price), with an exercise price of $11.3518 per share. The fair value of this warrant was estimated to be $0.1 million and accounted for as a debt discount. On August 5, 2019, in connection with the second amendment to the Runway Loan and Security Agreement, OTI amended the warrant issued to Runway Growth to increase the number of shares available to purchase to 53,023 shares of Series A Preferred Stock of OTI. The aggregate value of the warrants increased by $0.1 million after the warrant modification. The warrants were exercised on March 11, 2021 and the warrant liability was remeasured to fair value with the increase recognized as a loss of $0.6 million for the three and nine months ended September 30, 2021 within other income (expense), net in the consolidated statements of operations and comprehensive loss. The warrant liability was remeasured to fair value as of September 30, 2020 and the reduction was recognized as a gain of $0.2 million. On March 26, 2021 the Company terminated the Runway Loan and Security Agreement and repaid the $7.0 million principal amount outstanding as well as interest and fees amounting to $0.4 million. The Company incurred no prepayment fees in connection with the termination and all liens and security interests securing the loan made pursuant to the Runway Loan and Security Agreement were released upon termination. As of September 30, 2021 and December 31, 2020, the outstanding principal balance of the loan was nil and $7.0 million, respectively. Promissory notes

Warrants

Warrants	9 Months Ended
	Sep. 30, 2021
Equity [Abstract]
Warrants	Warrants Series A and B Redeemable Convertible Preferred Stock Warrants and Tranche Liability On November 27, 2018, in connection with the execution of the Runway Loan and Security Agreement, OTI issued a warrant to purchase 35,348 shares of Series A Preferred Stock of OTI at an exercise price of $11.3518 per share (the “Runway warrant”). On August 5, 2019, in connection with the second amendment to the Runway Loan and Security Agreement, OTI amended the Runway warrant to increase the number of shares available to purchase to 53,023 shares of Series A Preferred Stock of OTI at an exercise price of $11.3518 per share. The Runway warrants included a cashless exercise provision under which their holders could, in lieu of payment of the exercise price in cash, surrender the Runway warrant and receive a net amount of shares based on the fair market value of OTI’s stock at the time of exercise of the warrants after deduction of the aggregate exercise price. The Runway warrants contained provisions for adjustment of the exercise price and number of shares issuable upon the exercise of the Runway warrants in the event of certain stock dividends, stock splits, reorganizations, reclassifications, and consolidations. The fair value of the warrants issued was recorded as of the date of initial issuance in the amount of $0.1 million. The subsequent issuance of warrants pursuant to the August 5, 2019 amendment to the Runway Loan and Security Agreement was recorded in the amount of $0.1 million. Immediately prior to the Merger, the warrants were exercised in full in accordance with their terms. On April 3, 2020, in connection with the closing of the Series B redeemable convertible preferred stock, OTI issued a warrant to purchase 4,513,993 shares of Series B redeemable convertible preferred stock of the Company at an exercise price of $0.3323 per share (the “Series B warrants”). The Series B warrants could be exercised prior to the earliest to occur of (i) the 10 year anniversary of the date of issuance, (ii) the consummation of a liquidation transaction, or (iii) the consummation of an initial public offering. The Series B warrants included a cashless exercise provision under which their holders may, in lieu of payment of the exercise price in cash, surrender the warrant and receive a net amount of shares based on the fair market value of the Company’s stock at the time of exercise of the warrants after deduction of the aggregate exercise price. The Series B warrants contained provisions for adjustment of the exercise price and number of shares issuable upon the exercise of the Series B warrants in the event of certain stock dividends, stock splits, reorganizations, reclassifications, and consolidations. The Series B warrants were initially recognized as a liability at a fair value of $0.7 million. The Series B warrants were exercised on February 11, 2021 and the warrant liability was remeasured to fair value as of that date, resulting in a loss of $8.3 million for the nine months ended September 30, 2021, classified within other income (expense), net in the consolidated statements of operations and comprehensive loss. Upon exercise redeemable convertible preferred stock converted into common stock pursuant to the conversion rate effective immediately prior to the Merger. Historically, value was assigned to each class of equity securities using an option pricing model method (“OPM”). In September 2020, OTI began allocating the equity value using a hybrid method that utilizes a combination of the OPM and the probability weighted expected return method (“PWERM”). The PWERM is a scenario-based methodology that estimates the fair value of equity securities based upon an analysis of future values for OTI, assuming various outcomes. As the probability of a transaction with a special purpose acquisition company (“SPAC”) increased, the fair value of the redeemable convertible preferred stock warrant liability increased as of the date of the exercise. The redeemable convertible preferred stock warrants were valued using the following assumptions under the Black-Scholes option-pricing model: Initial Issuance Subsequent December 31, February 11, March 11, Stock price $ 5.80 $ 5.80 $ 7.11 $ 10.27 $ 8.44 Expected term (years) 10.00 9.31 2.00 2.00 2.00 Expected volatility 57.81 % 57.35 % 76.00 % 76.00 % 76.00 % Risk-free interest rate 3.06 % 1.75 % 0.13 % 0.13 % 0.13 % Dividend yield 0 % 0 % 0 % 0 % 0 % Series B Redeemable Convertible Preferred Stock Tranche In April 2020 and May 2020, OTI issued 62,505,102 shares of Series B redeemable convertible preferred stock at $0.3323 per share. For each share purchased, the purchaser had an option to purchase an additional share of Series B redeemable convertible preferred stock at $0.3323 per share, exercisable at any time prior to August 13, 2020 (the “Tranche Right”). The Company determined that the Tranche Right represented a freestanding obligation of the Company to issue additional shares of contingently redeemable shares if exercised by the holder. The freestanding redeemable convertible preferred stock tranche liability was initially recorded at fair value, with fair value changes recorded within other income (expense), net in the consolidated statements of operations and comprehensive loss. Private Placement Warrants Simultaneously with the closing of the Company’s initial public offering (the “IPO”) in August 2020, the sponsor of CLA, Colonnade Sponsor LLC, purchased an aggregate of 6,000,000 Private Placement warrants at a price of $1.00 per warrant, for an aggregate purchase price of $6,000,000. The Private Placement warrants became exercisable 12 months following the closing of the Company’s IPO, and will expire five years from the completion of the Merger, or earlier upon redemption or liquidation. Each Private Placement warrant is exercisable for one Class A ordinary share at a price of $11.50 per share. On March 11, 2021, each outstanding Private Placement warrant automatically converted into a warrant to purchase one share of Ouster common stock pursuant to the Warrant Agreement. The Private Placement warrants were initially recognized as a liability at a fair value of $19.4 million and the Private Placement warrant liability was remeasured to fair value as of March 31, 2021, June 30, 2021 and September 30, 2021, resulting in a gain of $14.5 million and $8.4 million for the three and nine months ended September 30, 2021, classified within other income (expense), net in the condensed consolidated statements of operations and comprehensive loss. The Private Placement warrants were valued using the following assumptions under the Black-Scholes option-pricing model: March 11, 2021 March 31, 2021 June 30, 2021 September 30, 2021 Stock price $ 12.00 $ 8.50 $ 12.49 $ 7.32 Exercise price of warrant 11.5 11.5 11.5 11.5 Expected term (years) 5.00 4.95 4.7 4.44 Expected volatility 27.00 % 43.00 % 43.00 % 46.00 % Risk-free interest rate 0.78 % 0.92 % 0.92 % 0.90 % Public Warrants CLA, in its IPO in August 2020, issued 20,000,000 units that each consisted of one Class A ordinary share and one half warrant to purchase a Class A ordinary share, which we refer to as CLA warrants before the Merger and Public warrants after the Merger. These warrants may only be exercised for a whole number of shares, and no fractional warrants were issued or issuable upon separation of the units and only whole warrants will trade. The warrants became exercisable 12 months following the closing of the Company’s IPO, and will expire five years from the completion of the Merger, or earlier upon redemption or liquidation. Each Public warrant is exercisable at a price of $11.50 per share. On March 11, 2021, upon the closing of the Merger pursuant to the Merger Agreement (Note 1), each of the 9,999,996 outstanding warrants, as adjusted for any fractional warrants that were not issued upon separation, was converted automatically into a redeemable Public warrant to purchase one share of the Company’s common stock. The Public warrants were recognized as equity upon the Merger in the amount of $17.9 million. Prior to their expiration, the Company may redeem the Public warrants at a price of $0.01 per warrant, provided that the closing price of the Company’s common stock equals or exceeds $18.00 per share for any 20 trading days within a 30 trading-day period ending on the third trading day prior to the date on which the Company gives proper notice of such redemption to the warrants holders.

Commitments and Contingencies

Commitments and Contingencies	9 Months Ended
	Sep. 30, 2021
Commitments and Contingencies Disclosure [Abstract]
Commitments and Contingencies	Commitments and Contingencies Letters of credit In connection with two leases, the Company obtained two letters of credit from a bank as required by the lease agreements. If the Company defaults under the terms of the applicable lease, the lessor will be entitled to draw upon the letters of credit in the amount necessary to cure the default. The amounts covered by the letters of credit are collateralized by certificates of deposit, which are included in restricted cash on the condensed consolidated balance sheets as of September 30, 2021 and December 31, 2020. The outstanding amount of the letters of credit was $1.3 million as of September 30, 2021 and December 31, 2020. Non-cancelable purchase commitments As of September 30, 2021, the Company had non-cancelable purchase commitments to a third-party contract manufacturer for approximately $6.4 million and other vendors for approximately $10.5 million. Litigation The Company is involved in various legal proceedings arising in the ordinary course of business. The Company accrues a liability when a loss is considered probable and the amount can be reasonably estimated. When a material loss contingency is reasonably possible but not probable, the Company does not record a liability, but instead discloses the nature and the amount of the claim, and an estimate of the loss or range of loss, if such an estimate can be made. Legal fees are expensed as incurred. Based on the opinion of legal counsel and other factors, management believes that the final disposition of these existing matters will not have a material adverse effect on the business, results of operations, financial condition, or cash flows of the Company. The Company has identified certain claims as a result of which a loss may be incurred, but in the aggregate any loss is expected to be immaterial. This assessment is based on our current understanding of relevant facts and circumstances. As such, our view of these matters is subject to inherent uncertainties and may change in the future. Significant judgment is required in both the determination of probability and the determination as to whether an exposure is reasonably estimable. Actual outcomes of these legal and regulatory proceedings may materially differ from our current estimates. For other claims regarding proceedings that are in an initial phase, the Company is unable to estimate the range of possible loss, if any, but at this time believes that any loss related to such claims will not be material. As of September 30, 2021 and December 31, 2020 there are no material litigation matters. Indemnification From time to time, the Company enters into agreements in the ordinary course of business that include indemnification provisions. Generally, in these provisions the Company agrees to defend, indemnify, and hold harmless the indemnified parties for claims and losses suffered or incurred by such indemnified parties for which the Company is responsible under the applicable indemnification provisions. The terms of the indemnification provisions vary depending upon negotiations between the Company and its counterpart; however, typically, these indemnification obligations survive the term of the contract and the maximum potential amount of future payments the Company could be required to make pursuant to these provisions are uncapped. To date, the Company has never incurred costs to defend lawsuits or settle claims related to these indemnification provisions. The Company has also entered into indemnity agreements pursuant to which it has indemnified its directors and officers, to the extent legally permissible, against all liabilities reasonably incurred in connection with any action in which such individual may be involved by reason of such individual being or having been a director or executive officer, other than liabilities arising from willful misconduct of the individual. To date, the Company has never incurred costs to defend lawsuits or settle claims related to these indemnity agreements. The unaudited condensed consolidated financial statements do not include a liability for any potential obligations under the indemnification agreements at September 30, 2021 and December 31, 2020.

Redeemable Convertible Preferre

Redeemable Convertible Preferred and Common Stock	9 Months Ended
	Sep. 30, 2021
Equity [Abstract]
Redeemable Convertible Preferred and Common Stock	Redeemable Convertible Preferred and Common Stock The Company’s common stock and warrants trade on the New York Stock Exchange under the symbol “OUST” and “OUSTWS”, respectively. Pursuant to the terms of the Second Amended and Restated Certificate of Incorporation, the Company is authorized and has available for issuance the following shares and classes of capital stock, each with a par value of $0.0001 per share: (i) 1,000,000,000 shares of common stock; (ii) 100,000,000 shares of preferred stock. Immediately following the Merger, there were 161,449,205 shares of common stock with a par value of $0.0001, and 15,999,996 warrants outstanding. The holder of each share of common stock is entitled to one vote. The Company has retroactively adjusted the shares issued and outstanding prior to March 11, 2021 to give effect to the exchange ratio established in the Merger Agreement to determine the number of shares of common stock into which they were converted. Immediately prior to the Merger, OTI’s certificate of incorporation, as amended, authorized it to issue 342,367,887 shares of $0.00001 par value, with 210,956,516 shares designated as common stock and 131,411,372 shares of redeemable convertible preferred stock. Series Seed Financing and conversion In April 2016, OTI issued 1,887,253 shares of Series Seed redeemable convertible preferred stock at $1.02 per share for net proceeds of $1.8 million, net of $0.1 million stock issuance costs. In April 2016, OTI issued 44,256 shares to an investor upon conversion of a note having a balance of principal and interest of $45,000. In May 2016, OTI issued 563,725 shares of Series Seed redeemable convertible preferred stock at $1.02 per share for net proceeds of $0.6 million. In July 2016, OTI issued 445,942 shares of Series Seed redeemable convertible preferred stock at $1.02 per share for net proceeds of $0.5 million. In April 2020, in order to induce the closing of the Series B Financing, the holders exercised the embedded conversion feature and all the outstanding Series Seed redeemable convertible preferred stock shares were converted to 2,941,176 shares of OTI’s common stock. Series A Financing and conversion In October 2017, OTI issued 1,324,511 shares of Series A Preferred Stock at $11.3158 per share for net proceeds of $14.8 million, net of $0.2 million of stock issuance costs. In October 2017, OTI issued 1,253,556 shares of Series A Preferred Stock upon conversion of multiple notes having a principal and interest balance of $4.6 million. In December 2017, OTI issued 715,712 shares of Series A Preferred Stock at $11.3158 per share for net proceeds of $8.1 million. In April 2020, in order to induce the closing of the Series B Financing, the holders exercised the embedded conversion feature and all of the outstanding Series A redeemable convertible preferred stock shares were converted to 3,293,779 shares of OTI’s common stock. Series B Financing In April 2020, OTI issued 45,185,071 shares of Series B redeemable convertible preferred stock at $0.3323 per share for net proceeds of $15.1 million, less $0.1 million of stock issuance costs. In May 2020, OTI issued 17,320,031 shares of Series B redeemable convertible preferred stock at $0.3323 per share for net proceeds of $5.8 million, less $0.1 million of stock issuance costs. In July 2020, OTI issued 37,970,846 shares of Series B redeemable convertible preferred stock at $0.3323 per share for net proceeds of $12.5 million, less $0.1 million of stock issuance costs. In August 2020, OTI issued 25,286,587 shares of Series B redeemable convertible preferred stock at $0.3323 per share for net proceeds of $8.4 million, less $0.1 million of stock issuance costs. On March 11, 2021, upon the closing of the Transaction pursuant to the Merger Agreement (Note 1), all of the outstanding redeemable convertible preferred stock was converted to the Company’s common stock pursuant to the conversion rate effective immediately prior to the Transaction and the remaining amount was reclassified to additional paid-in capital. As of September 30, 2021, the Company does not have any redeemable convertible preferred stock outstanding. Prior to the Merger, redeemable convertible preferred stock as of December 31, 2020, consisted of the following (in thousands, except share and per share data): December 31, 2020 Series Issue Price Shares Shares Liquidation Carrying Series B $ 0.33 131,411,372 88,434,754 $ 41,791 $ 39,225 Prior to the Merger, the significant features of OTI’s redeemable convertible preferred stock were as follows: Dividend provisions The Series Seed, Series A and Series B preferred stockholders are entitled to receive dividends prior and in preference to any dividends on the common stock, at a rate of $0.0612, $0.6789 and $0.019938 per share, respectively, per annum on a non-cumulative basis, when and if declared by the board of directors, subject to the prior rights of the preferred stockholders. After payment of such dividend, any additional dividends would be distributed among the holders of the preferred stock and common stock pro rata based on the number of shares of common stock then held by each holder (assuming conversion of all shares of preferred stock into common stock). Liquidation preference In the event of liquidation, dissolution or winding up of OTI, merger or a reduction of capital through the sale or lease of all or substantial part of the business of OTI, before any distribution or payment were to be made to the holders of common stock, the holders of Series Seed, Series A and Series B redeemable convertible preferred stock were entitled to receive $1.02, $11.3518 and $0.3323 per share (subject to adjustment in the event of any share dividend, share split, combination, or other recapitalization), respectively, plus any declared but unpaid dividends on such shares. If the assets and funds were insufficient for such distribution, they were entitled to receive a pro rata distribution, based on the relative preferred stock ownership and in proportion to the preferential amount each such holder is otherwise entitled. If the assets and funds are in excess of amounts distributed to the preferred stockholders, the remaining assets and funds shall be distributed pro rata to the holders of the common stock. If the holders of the redeemable convertible preferred stock would receive a greater distribution if they converted to common stock, then such conversion would have been assumed prior to distribution. Conversion rights The holders of Series Seed, Series A and Series B redeemable convertible preferred stock had a right to convert their stock into nonassessable shares of common stock at a conversion rate equal to their respective liquidation preferences divided by a conversion price of $1.02, $11.3518 and $0.3323, respectively, which was adjusted for any stock splits, stock dividends, combination, subdivisions, recapitalizations or similar transactions. On March 11, 2021, upon the closing of the Transaction pursuant to the Merger Agreement (Note 1), all of the outstanding redeemable convertible preferred stock was converted to the Company’s common stock pursuant to the conversion rate effective immediately prior to the Transaction and the remaining amount was reclassified to additional paid-in capital. Redemption rights The redeemable convertible preferred stock were recorded in mezzanine equity because while it was not currently redeemable, it could become redeemable at the option of the preferred stockholders upon the occurrence of certain deemed liquidation events that were considered not solely within OTI’s control for an amount equal to the shares respective liquidation preference plus declared and unpaid dividends. Voting rights

Stock-based compensation

Stock-based compensation	9 Months Ended
	Sep. 30, 2021
Share-based Payment Arrangement [Abstract]
Stock-based compensation	Stock-based compensation As of September 30, 2021, we have two equity incentive plans, our 2015 Stock Plan (the “2015 Plan”) and our 2021 Incentive Award Plan (the “2021 Plan”). As of March 11, 2021, we no longer grant equity awards pursuant to our 2015 Plan, but it continues to govern the terms of outstanding stock options that were granted prior to that date. On October 12, 2020, OTI issued $1.1 million partial recourse promissory notes to certain executives and employees. The promissory notes carried 0.38% annual cash interest and were due on earliest of 9th anniversary of the date of issuance of the notes, or termination of employment of the executive/employee, or filing by OTI of a registration statement under the Securities Act of 1933, or promissory notes being prohibited under Section 13(k) of the Securities Exchange Act of 1934 or closing of change a in control of OTI. At issuance, the promissory notes were used to settle certain executives’ and employees’ obligations for 2,883,672 vested and 4,603,833 unvested ISOs that were exercised and no cash was exchanged. In March 2021, in connection with the close of the Merger, the Company forgave half of the respective obligations under the promissory notes for certain executives and required such noteholders to repay the remaining balance of $0.3 million under each of their respective notes. Additional compensation expense of $0.3 million was recognized in general and administrative expenses in the three months ended March 31, 2021 and the nine months ended September 30, 2021 for the value of the loans forgiven. Obligations under the promissory notes for non-executive noteholders of $0.5 million is outstanding as of September 30, 2021. 2021 Incentive Award Plan On March 11, 2021, the Board of Directors approved the 2021 Plan. The 2021 Plan provides for the grant of stock options, stock appreciation rights, restricted stock units, performance stock unit awards and other forms of equity compensation (collectively, “equity awards”). In addition, the 2021 Plan provides for the grant of performance bonus awards. All awards within the 2021 Plan may be granted to employees, including officers, as well as directors and consultants, within the limit defined in the 2021 Plan. 18,558,576 shares of the Company’s common stock were initially reserved for issuance under the 2021 Plan. The 2021 Plan includes an evergreen provision that provides for an annual increase in the number of shares of common stock available for issuance thereunder beginning on January 1, 2022 and ending on January 1, 2031, equal to 5% of the shares of Company common stock outstanding on the last day of the immediately preceding fiscal year and such smaller number of shares as determined by the Board of Directors or a committee thereof. As of September 30, 2021, the Company had 13,680,487 shares of common stock available pursuant to new awards under the 2021 Plan. Options and stock appreciation rights under the 2021 Plan will be exercisable at such times and as specified in the Award Agreement (as defined in the 2021 Plan) provided that the term of an option or stock appreciation will not exceed ten years. Options granted under the 2021 Plan may be Incentive Stock Options (ISOs) or Non-statutory Stock Options, as determined by the Administrator at the time of grant of an option and subject to the applicable provisions of Section 422 of the Internal Revenue Code and the regulations promulgated thereunder. The exercise price of an option will be no less than 100% of the fair market value of the shares of common stock on the date of grant. The exercise price of an ISO granted to a 10% shareholder will be no less than 110% of the fair market value of the shares on the date of grant and the term of the ISO will not exceed five years. The Company granted an option to purchase 1,614,492 shares of Company common stock to a senior advisor serving on the Company’s board of directors as chair with 20% of the total number of such option shares vesting on each of the first five equals or exceeds 130% of the exercise price per share of the option for 30 consecutive trading days. The senior advisor has resigned in June 2021 and the option to purchase 1,614,492 shares of Company common stock was forfeited. Restricted stock and restricted stock units granted to employees generally vest as to 25% of the shares on the first anniversary service date of the grant, and quarterly thereafter so as to be 100% vested on the four five In March 2021, the Company also granted 152,628 restricted stock units to several members of the board of directors subject to standard terms of these awards. Vesting schedules for performance stock unit awards and other equity awards vary and are linked to one or more of performance or other specific criteria, including service to the Company, determined to be appropriate by the Board, in each case on a specified date or dates or over any period or periods determined by the Board. The performance condition awards are automatically forfeited in their entirety, without any cost to or action by the Company, if there has been no achievement of the performance condition. The Company granted 807,246 performance stock units to a senior advisor who serves as chair of the board of directors with vesting earned over four years based on achieving increases in the Company’s stock price from the date of grant ranging from 150%, to earn 25% of the performance stock units, to 300% to earn the entire award of performance stock units. Each performance stock unit constitutes the right to receive one share of Company common stock upon vesting. As noted above, the senior advisor has resigned in June 2021 and all performance stock unit awards granted were forfeited. Performance bonus awards are denominated in cash, stock or a combination thereof, and shall be payable upon the attainment of performance goals that are established by the Board and relate to one or more of performance or other specific criteria, including service to the Company, in each case on a specified date or dates or over any period or periods determined by the Board. Stock option activity for the nine months ended September 30, 2021 is as follows: Number of Weighted- Weighted- Aggregate Outstanding—December 31, 2020 25,732,503 $ 0.39 9.60 $ 245,746 Options granted 645,796 10.26 Options exercised (913,279) 0.14 Options cancelled (505,213) 0.14 Outstanding—September 30, 2021 24,959,807 $ 0.67 8.7 $ 167,460 Vested and expected to vest—September 30, 2021 24,959,807 $ 0.67 8.7 $ 167,460 Exercisable—September 30, 2021 8,844,727 $ 0.31 8.1 $ 61,987 The following table summarizes the weighted-average assumptions used in estimating the fair value of options granted in the nine months ended September 30, 2021, using the Black-Scholes option-pricing model: Nine Months Ended September 30, 2021 Expected term (years) 6.00 Expected volatility 63.19 % Risk-free interest rate 1.03 % Expected dividend rate — % The following table summarizes information about stock options outstanding and exercisable at September 30, 2021. Options Outstanding Options Exercisable Exercise Options Weighted Weighted Options Weighted Weighted $ 0.18 6,350,481 8.3 $ 0.18 3,889,338 7.8 $ 0.18 $ 0.21 10,394,961 8.8 $ 0.21 3,186,660 8.2 $ 0.21 $ 0.37 35,159 0.4 $ 0.37 35,159 0.4 $ 0.37 $ 1.42 7,524,116 9 $ 1.42 1,724,276 9 $ 1.42 $ 5.57 7,976 0.2 $ 5.57 7,976 0.2 $ 5.57 $ 8.25 1,318 0.2 $ 8.25 1,318 0.2 $ 8.25 $ 10.26 645,796 9.5 $ 10.26 — $ — 24,959,807 8,844,727 The weighted average grant date fair value of options granted during the nine months ended September 30, 2021 was $5.9. As of September 30, 2021, there was approximately $27.5 million of unamortized stock-based compensation expense related to unvested stock options that is expected to be recognized over a weighted average period of 1.7 years. Restricted Stock Awards (“RSA”) A summary of RSA activity under the 2015 Plan is as follows: Number of Weighted Average Grant Date Fair Value (per share) Unvested – December 31, 2020 40,754 $ 0.67 Granted during the period — — Canceled during the period — — Vested during the period (17,466) 0.67 Unvested — September 30, 2021 23,288 $ 0.67 The weighted-average estimated fair value of RSAs granted in the nine months ended September 30, 2021 was Nil per share. The total fair value of RSAs vested during the nine months ended September 30, 2021 was less than $0.1 million. Restricted Stock Units (“RSU”) A summary of RSU activity is as follows: Number of Weighted Average Grant Date Fair Value (per share) Unvested – December 31, 2020 — $ — Granted during the period 4,332,224 9.50 Canceled during the period (27,636) 8.86 Vested during the period (463,043) 10.46 Unvested — September 30, 2021 3,841,545 $ 9.21 Stock compensation expense is recognized on a straight-line basis over the vesting period of each RSU. As of September 30, 2020, total compensation expense related to unvested RSUs granted to employees, but not yet recognized, was $34.2 million, with a weighted-average remaining vesting period of 3.2 years. The Company recognized stock-based compensation for all stock options in the condensed consolidated statements of operations and comprehensive loss as follows (in thousands): Three Months Ended September 30, Nine Months Ended September 30, 2021 2020 2021 2020 Cost of revenue $ 206 $ 505 $ 457 $ 606 Research and development 2,063 4,889 4,305 5,177 Sales and marketing 1,717 319 2,702 408 General and administrative 3,161 1,543 11,093 1,700 Total stock-based compensation $ 7,147 $ 7,256 $ 18,557 $ 7,891

Net Loss Per Common Share

Net Loss Per Common Share	9 Months Ended
	Sep. 30, 2021
Earnings Per Share [Abstract]
Net Loss Per Common Share	Net Loss Per Common Share The following table sets forth the computation of basic and diluted net loss per common share attributable to common stockholders (in thousands, except share and per share data): Three Months Ended September 30, Nine Months Ended September 30, 2021 2020 2021 2020 Numerator: Net loss $ (12,669) $ (19,615) $ (65,637) $ (49,620) Denominator: Weighted average shares used to compute basic and diluted net loss per share 156,647,259 20,303,631 123,175,390 15,753,057 Net loss per common share—basic and diluted $ (0.08) $ (0.97) $ (0.53) $ (3.15) The shares and net loss per common share, prior to the Merger, have been retroactively restated as shares reflecting the exchange ratio of approximately 0.703 shares of the Company per one share of OTI as established in the Merger Agreement. The weighted average number of shares used to compute basic and diluted net loss per share excludes unvested early exercised common stock options subject to repurchase. The following outstanding shares of potentially dilutive securities were excluded from the computation of diluted net loss per share attributable to common stockholders for the periods presented because including them would have been antidilutive: As of September 30, 2021 2020 Redeemable convertible preferred stock — 88,434,754 Options to purchase common stock 24,959,807 22,699,012 Unvested RSA 23,288 237,798 Restricted stock units 4,304,588 — Unvested early exercised common stock options 2,234,455 30,421 Vested and early exercised options subject to nonrecourse notes 2,172,238 — Preferred stock warrants — 4,443,862 Public and private common stock warrants 15,999,996 — Total 49,694,372 115,845,847

Income taxes

Income taxes	9 Months Ended
	Sep. 30, 2021
Income Tax Disclosure [Abstract]
Income taxes	Income taxes The Company’s income tax provision for interim periods is determined using an estimate of the Company’s annual effective tax rate, adjusted for discrete items arising in the quarter. The Company’s effective tax rate differs from the U.S. statutory tax rate primarily due to valuation allowances on the deferred tax assets as it is more likely than not that some, or all, of the Company’s deferred tax assets will not be realized. The Company continues to maintain a full valuation allowance against its net deferred tax assets. Due to tax losses and the offsetting valuation allowance, the income tax provision for the three and nine months ended September 30, 2021 and 2020 was not material to the Company’s condensed consolidated financial statements.

Revenue

Revenue	9 Months Ended
	Sep. 30, 2021
Revenue from Contract with Customer [Abstract]
Revenue	Revenue Revenue from sale of lidar sensor kits, which are recognized at a point in time, was $7.8 million and $5.9 million in three months ended September 30, 2021 and 2020, respectively, and $21.7 million and $10.5 million in nine months ended September 30, 2021 and 2020, respectively. The following table presents total revenues by geographic area based on the location products were shipped to and services provided (in thousands): Three Months Ended September 30, Nine Months Ended September 30, 2021 2020 2021 2020 United States $ 4,037 $ 2,288 $ 8,463 $ 6,349 Americas, excluding United States 147 85 675 194 Europe, Middle East and Africa 1,614 1,366 7,684 2,634 Asia and Pacific 1,957 2,208 4,904 3,351 Total $ 7,755 $ 5,947 $ 21,726 $ 12,528

Related Party Transactions

Related Party Transactions	9 Months Ended
	Sep. 30, 2021
Related Party Transactions [Abstract]
Related Party Transactions	Related Party Transactions See Note 5 , Debt for details of promissory notes issued by the Company to certain investors of the Company (or an affiliate thereof). See Note 9

Subsequent Event

Subsequent Event	9 Months Ended
	Sep. 30, 2021
Subsequent Events [Abstract]
Subsequent Event	Subsequent Event On October 5, 2021, the Company announced its intent to acquire privately held Sense Photonics, Inc. ("Sense"), a lidar technology company for autonomous vehicles. On October 22, 2021, the Company completed its acquisition of Sense and formally established Ouster Automotive, a new functional division of the Company focusing on driving mass-market adoption of digital lidar in consumer and commercial vehicles. Under the terms of the merger agreement, Ouster acquired 100% of Sense and all of its property for approximately 10 million shares of Ouster common stock or approximately $63 million in equity value based on the closing price of $6.55 per share as of the day the transaction closed on October 22, 2021, inclusive of 0.8 million shares underlying assumed options, after closing adjustments. The initial purchase price accounting for the business combination is in progress at this time due to the pending completion of the valuation analysis over the acquired assets.

Summary of Significant Accoun_2

Summary of Significant Accounting Policies (Policies)	9 Months Ended
	Sep. 30, 2021
Accounting Policies [Abstract]
Basis of Presentation and Principles of Consolidation	Basis of Presentation and Principles of Consolidation The unaudited condensed consolidated financial statements include the accounts of the Company and its subsidiaries (all of which are wholly owned) and have been prepared in conformity with U.S. generally accepted accounting principles (“US GAAP”) applicable to interim periods. The functional currency for the Company is the United States dollar. All intercompany balances and transactions have been eliminated in consolidation. The unaudited condensed consolidated financial statements include all adjustments (consisting of only normal recurring adjustments) necessary for a fair statement of the results of operations for the periods shown. The unaudited condensed consolidated financial statements should be read in conjunction with the Company’s audited consolidated financial statements as of and for the year ended December 31, 2020 and the notes related thereto, included as Exhibit 99.1 to the Form 8-K filed with the Securities and Exchange Commission (“SEC”) on March 15, 2021, as amended on July 12, 2021. The year-end condensed balance sheet data was derived from audited financial statements, but does not include all disclosures required by US GAAP. Certain information and note disclosures normally included in the audited financial statements prepared in accordance with US GAAP have been condensed or omitted from this report, as is permitted by such rules and regulations. The results of operations for any interim period are not necessarily indicative of the results to be expected for the year ending December 31, 2021 or for any other future years or interim periods.
Merger	The Merger was accounted for as a reverse recapitalization under US GAAP. Under this method of accounting, CLA is treated as the “acquired” company for financial reporting purposes. This determination is primarily based on OTI stockholders comprising a relative majority of the voting power of the Company and having the ability to nominate the members of the board of directors of the Company after the Merger, OTI’s operations prior to the Merger comprising the only ongoing operations of the Company following the Merger, and OTI’s senior management prior to the Merger comprising a majority of the senior management of the Company following the Merger. Accordingly, for accounting purposes, the financial statements of the Company represent a continuation of the financial statements of OTI with the Merger being treated as the equivalent of OTI issuing stock for the net assets of CLA, accompanied by a recapitalization whereby no goodwill or other intangible assets are recorded. Transactions and balances prior to the Merger are those of OTI. The shares and net loss per share available to holders of OTI’s common stock prior to the Merger have been retroactively restated as shares reflecting the exchange ratio established in the Merger Agreement.
Recently Issued Accounting Pronouncements	Recently Issued Accounting Pronouncements Based on our public float as of June 30, 2021, we expect to become a large accelerated filer, and lose emerging growth company status, as of December 31, 2021. As of December 31, 2021, we will be required to adopt new or revised accounting standards when they are applicable to public companies that are not emerging growth companies. In June 2016, the FASB issued ASU 2016-13, Financial Instruments—Credit Losses (Topic 326), to introduce a new impairment model for recognizing credit losses on financial instruments based on an estimate of current expected credit losses (“ECL”). Under the new model, an entity is required to estimate ECL on available-for-sale (AFS) debt securities only when the fair value is below the amortized cost of the asset and is no longer based on an impairment being “other-than-temporary”. The new model also requires the impairment calculation on an individual security level and requires an entity to use the present value of cash flows when estimating the ECL. The credit-related losses are required to be recognized through earnings and non-credit related losses are reported in other comprehensive income. The Company will adopt ASC 2016-13 for the December 31, 2021 annual period, with a modified retrospective application to all outstanding instruments and a cumulative effect adjustment recorded to opening retained earnings as of January 1, 2021. The Company does not believe the adoption of this new guidance will have a material impact on its consolidated financial statements. In August 2018, the FASB issued ASU 2018-15, Intangibles-Goodwill and Other-Internal-Use Software (Subtopic 350-40): Customer’s Accounting for Implementation Costs Incurred in a Cloud Computing Arrangement That Is a Service Contract, which aligns the requirements for capitalizing implementation costs incurred in a cloud computing arrangement that is a service contract with the requirements for capitalizing implementation costs incurred to develop or obtain internal-use software. The Company will adopt ASC 2018-15 for the December 31, 2021 annual period. The Company does not believe the adoption of this new guidance will have a material impact on its consolidated financial statements. In August 2020, the FASB issued ASU No. 2020-06, Debt – Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging – Contracts in Entity’s Own Equity (Subtopic 815-40): Accounting for Convertible Instruments and Contracts in an Entity’s Own Equity (“ASU 2020-06). ASU 2020-06 simplifies the accounting for convertible debt and convertible preferred stock by removing the requirements to separately present certain conversion features in equity. In addition, the amendments in the ASU also simplify the guidance in ASC 815-40, Derivatives and Hedging: Contracts in Entity’s Own Equity, by removing certain criteria that must be satisfied in order to classify a contract as equity, which is expected to decrease the number of freestanding instruments and embedded derivatives accounted for as assets or liabilities. Finally, the amendments revise the guidance on calculating earnings per share, requiring use of the if-converted method for all convertible instruments and rescinding an entity’s ability to rebut the presumption of share settlement for instruments that may be settled in cash or other assets. The new standard is effective for the Company for annual periods beginning December 15, 2021. The Company is currently evaluating the impact of the adoption of this ASU on the Company’s condensed consolidated financial statements. In October 2021, the FASB issued ASU 2018-08, Business Combinations (Topic 805): Accounting for Contract Assets and Contract Liabilities from Contracts with Customers, which amends ASC 805 to add contract assets and contract liabilities to the list of exceptions to the recognition and measurement principles that apply to business combinations and to require that an entity (acquirer) recognize and measure contract assets and contract liabilities acquired in a business combination in accordance with Topic 606. The amendments in this ASU are effective for fiscal years beginning after December 15, 2022, including interim periods within those fiscal years and should be applied prospectively to business combinations occurring on or after the effective date of the amendments. Early adoption of the amendments is permitted, including adoption in an interim period. The Company is currently evaluating the impact of the adoption of this ASU on the Company’s condensed consolidated financial statements.
Concentrations of credit risk	Concentrations of credit risk Financial instruments that potentially subject the Company to credit risk consist primarily of cash, cash equivalents, and restricted cash, and accounts receivable. Cash, cash equivalents and restricted cash are deposited with federally insured commercial banks in the United States and at times cash balances may be in excess of federal insurance limits. The Company generally does not require collateral or other security deposits for accounts receivable.

Summary of Significant Accoun_3

Summary of Significant Accounting Policies (Tables)	9 Months Ended
	Sep. 30, 2021
Accounting Policies [Abstract]
Schedules of Concentration of Risk	Accounts receivable from the Company’s major customers representing 10% or more of total accounts receivable was as follows: September 30, December 31, Customer A * 13 % Customer B * 23 % Customer C 14 % * * Customer accounted for less than 10% of total accounts receivable as of such date. Revenue from the Company’s major customers representing 10% or more of total revenue was as follows: Three Months Ended September 30, Nine Months Ended September 30, 2021 2020 2021 2020 Customer D * * 10 % * Customer E * * * 16 % * Customer accounted for less than 10% of total revenue in the period. Purchases from the Company’s major suppliers representing 10% or more of total purchases were as follows: Three Months Ended September 30, Nine Months Ended September 30, 2021 2020 2021 2020 Supplier A 19 % 19 % 17 % 15 %

Fair Value of Financial Instr_2

Fair Value of Financial Instruments (Tables)	9 Months Ended
	Sep. 30, 2021
Fair Value Disclosures [Abstract]
Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis	The following table provides information by level for the Company’s assets and liabilities that were measured at fair value on a recurring basis (in thousands): September 30, 2021 Level 1 Level 2 Level 3 Total Assets Money market funds $ 219,276 $ — $ — $ 219,276 Total financial assets $ 219,276 $ — $ — $ 219,276 Liabilities Warrant liabilities $ — $ — $ 10,979 $ 10,979 Total financial liabilities $ — $ — $ 10,979 $ 10,979 December 31, 2020 Level 1 Level 2 Level 3 Total Assets Money market funds $ 10,493 $ — $ — $ 10,493 Total financial assets $ 10,493 $ — $ — $ 10,493 Liabilities Warrant liabilities $ — $ — $ 49,293 $ 49,293 Total financial liabilities $ — $ — $ 49,293 $ 49,293
Schedule of Changes in Fair Value of Level 3 Financial Instruments	The following table presents a summary of the changes in the fair value of the Company’s Level 3 financial instruments (in thousands): Redeemable Redeemable Private Placement Warrant Liability Derivative Fair value as of January 1, 2020 $ (162) $ — $ — $ — Change in the fair value included in other income (expense), net (6,097) — — (5,308) Recognition of preferred stock warrant and tranche liability upon issuance (691) (1,610) — — Extinguishment of derivative liability upon conversion of convertible notes — — — 5,308 Fair value as of Settlement of redeemable convertible preferred stock tranche liability due to the issuance of Series B redeemable convertible preferred stock — 1,610 — — Fair value as of September 30, 2020 $ (6,950) $ — $ — $ — Fair value as of January 1, 2021 $ (49,293) $ — $ — $ — Private placement warrant liability acquired as part of the Merger — — (19,377) — Change in the fair value included in other income (expense), net (8,804) — 8,398 — Issuance of preferred stock upon exercise of warrants 58,097 — — — Fair value as of September 30, 2021 $ — $ — $ (10,979) $ —

Balance Sheet Components (Table

Balance Sheet Components (Tables)	9 Months Ended
	Sep. 30, 2021
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Schedule of Cash and Cash Equivalents	The Company’s cash and cash equivalents consist of the following (in thousands): September 30, December 31, Cash $ 2,300 $ 869 Cash equivalents: Money market funds (1) 219,276 10,493 Total cash and cash equivalents $ 221,576 $ 11,362 (1) The Company maintains a cash sweep account which is included in money market funds as of September 30, 2021. Cash is invested in the short-term money market funds, which is a cash sweep for uninvested cash that earns interest. Reconciliation of cash, cash equivalents and restricted cash as shown in the condensed consolidated statement of cash flows to the respective accounts within the condensed consolidated balance sheet is as follows (in thousands): September 30, September 30, Cash and cash equivalents $ 221,576 $ 18,367 Restricted cash, current 1,008 276 Restricted cash, non-current 1,004 1,280 Total cash, cash equivalents and restricted cash $ 223,588 $ 19,923
Schedule of Inventory	Inventory, consisting of material, direct and indirect labor, and manufacturing overhead, consists of the following (in thousands): September 30, December 31, Raw materials $ 2,269 $ 1,376 Work in process 2,165 1,249 Finished goods 2,068 2,192 Total inventory $ 6,502 $ 4,817
Schedule of Prepaid Expenses and Other Current Assets	Prepaid expenses and other current assets consist of the following (in thousands): September 30, December 31, Prepaid insurance $ 3,473 $ 206 Prepaid expenses 1,583 694 Receivable from contract manufacturer 53 1,521 Security deposit 1,179 20 Total prepaid and other current assets $ 6,288 $ 2,441
Schedule of Accrued and Other Current Liabilities	Accrued and other current liabilities consist of the following (in thousands): September 30, December 31, Customer deposits $ 48 $ 71 Accrued compensation 2,640 1,618 Uninvoiced receipts 7,726 1,947 Other 1,024 485 Total accrued and other current liabilities $ 11,438 $ 4,121

Warrants (Tables)

Warrants (Tables)	9 Months Ended
	Sep. 30, 2021
Equity [Abstract]
Schedule of Fair Value Measurement Inputs	The redeemable convertible preferred stock warrants were valued using the following assumptions under the Black-Scholes option-pricing model: Initial Issuance Subsequent December 31, February 11, March 11, Stock price $ 5.80 $ 5.80 $ 7.11 $ 10.27 $ 8.44 Expected term (years) 10.00 9.31 2.00 2.00 2.00 Expected volatility 57.81 % 57.35 % 76.00 % 76.00 % 76.00 % Risk-free interest rate 3.06 % 1.75 % 0.13 % 0.13 % 0.13 % Dividend yield 0 % 0 % 0 % 0 % 0 % The Private Placement warrants were valued using the following assumptions under the Black-Scholes option-pricing model: March 11, 2021 March 31, 2021 June 30, 2021 September 30, 2021 Stock price $ 12.00 $ 8.50 $ 12.49 $ 7.32 Exercise price of warrant 11.5 11.5 11.5 11.5 Expected term (years) 5.00 4.95 4.7 4.44 Expected volatility 27.00 % 43.00 % 43.00 % 46.00 % Risk-free interest rate 0.78 % 0.92 % 0.92 % 0.90 %

Redeemable Convertible Prefer_2

Redeemable Convertible Preferred and Common Stock (Tables)	9 Months Ended
	Sep. 30, 2021
Equity [Abstract]
Schedule of Redeemable Convertible Preferred Stock	Prior to the Merger, redeemable convertible preferred stock as of December 31, 2020, consisted of the following (in thousands, except share and per share data): December 31, 2020 Series Issue Price Shares Shares Liquidation Carrying Series B $ 0.33 131,411,372 88,434,754 $ 41,791 $ 39,225

Stock-based compensation (Table

Stock-based compensation (Tables)	9 Months Ended
	Sep. 30, 2021
Share-based Payment Arrangement [Abstract]
Schedule of Stock Option Activity	Stock option activity for the nine months ended September 30, 2021 is as follows: Number of Weighted- Weighted- Aggregate Outstanding—December 31, 2020 25,732,503 $ 0.39 9.60 $ 245,746 Options granted 645,796 10.26 Options exercised (913,279) 0.14 Options cancelled (505,213) 0.14 Outstanding—September 30, 2021 24,959,807 $ 0.67 8.7 $ 167,460 Vested and expected to vest—September 30, 2021 24,959,807 $ 0.67 8.7 $ 167,460 Exercisable—September 30, 2021 8,844,727 $ 0.31 8.1 $ 61,987
Schedule of Stock Options Valuation Assumptions	The following table summarizes the weighted-average assumptions used in estimating the fair value of options granted in the nine months ended September 30, 2021, using the Black-Scholes option-pricing model: Nine Months Ended September 30, 2021 Expected term (years) 6.00 Expected volatility 63.19 % Risk-free interest rate 1.03 % Expected dividend rate — %
Schedule of Stock Options Outstanding and Exercisable	The following table summarizes information about stock options outstanding and exercisable at September 30, 2021. Options Outstanding Options Exercisable Exercise Options Weighted Weighted Options Weighted Weighted $ 0.18 6,350,481 8.3 $ 0.18 3,889,338 7.8 $ 0.18 $ 0.21 10,394,961 8.8 $ 0.21 3,186,660 8.2 $ 0.21 $ 0.37 35,159 0.4 $ 0.37 35,159 0.4 $ 0.37 $ 1.42 7,524,116 9 $ 1.42 1,724,276 9 $ 1.42 $ 5.57 7,976 0.2 $ 5.57 7,976 0.2 $ 5.57 $ 8.25 1,318 0.2 $ 8.25 1,318 0.2 $ 8.25 $ 10.26 645,796 9.5 $ 10.26 — $ — 24,959,807 8,844,727
Schedule of Nonvested Restricted Stock Awards Activity	A summary of RSA activity under the 2015 Plan is as follows: Number of Weighted Average Grant Date Fair Value (per share) Unvested – December 31, 2020 40,754 $ 0.67 Granted during the period — — Canceled during the period — — Vested during the period (17,466) 0.67 Unvested — September 30, 2021 23,288 $ 0.67
Schedule of Nonvested Restricted Stock Units Activity	A summary of RSU activity is as follows: Number of Weighted Average Grant Date Fair Value (per share) Unvested – December 31, 2020 — $ — Granted during the period 4,332,224 9.50 Canceled during the period (27,636) 8.86 Vested during the period (463,043) 10.46 Unvested — September 30, 2021 3,841,545 $ 9.21
Schedule of Stock-based Compensation	The Company recognized stock-based compensation for all stock options in the condensed consolidated statements of operations and comprehensive loss as follows (in thousands): Three Months Ended September 30, Nine Months Ended September 30, 2021 2020 2021 2020 Cost of revenue $ 206 $ 505 $ 457 $ 606 Research and development 2,063 4,889 4,305 5,177 Sales and marketing 1,717 319 2,702 408 General and administrative 3,161 1,543 11,093 1,700 Total stock-based compensation $ 7,147 $ 7,256 $ 18,557 $ 7,891

Net Loss Per Common Share (Tabl

Net Loss Per Common Share (Tables)	9 Months Ended
	Sep. 30, 2021
Earnings Per Share [Abstract]
Schedule of Net Loss Per Common Share, Basic and Diluted	The following table sets forth the computation of basic and diluted net loss per common share attributable to common stockholders (in thousands, except share and per share data): Three Months Ended September 30, Nine Months Ended September 30, 2021 2020 2021 2020 Numerator: Net loss $ (12,669) $ (19,615) $ (65,637) $ (49,620) Denominator: Weighted average shares used to compute basic and diluted net loss per share 156,647,259 20,303,631 123,175,390 15,753,057 Net loss per common share—basic and diluted $ (0.08) $ (0.97) $ (0.53) $ (3.15) The shares and net loss per common share, prior to the Merger, have been retroactively restated as shares reflecting the exchange ratio of approximately 0.703 shares of the Company per one share of OTI as established in the Merger Agreement. The weighted average number of shares used to compute basic and diluted net loss per share excludes unvested early exercised common stock options subject to repurchase.
Schedule of Antidilutive Securities Excluded from Computation of Net Loss Per Common Share	The following outstanding shares of potentially dilutive securities were excluded from the computation of diluted net loss per share attributable to common stockholders for the periods presented because including them would have been antidilutive: As of September 30, 2021 2020 Redeemable convertible preferred stock — 88,434,754 Options to purchase common stock 24,959,807 22,699,012 Unvested RSA 23,288 237,798 Restricted stock units 4,304,588 — Unvested early exercised common stock options 2,234,455 30,421 Vested and early exercised options subject to nonrecourse notes 2,172,238 — Preferred stock warrants — 4,443,862 Public and private common stock warrants 15,999,996 — Total 49,694,372 115,845,847

Revenue (Tables)

Revenue (Tables)	9 Months Ended
	Sep. 30, 2021
Revenue from Contract with Customer [Abstract]
Schedule of Disaggregation of Revenue	The following table presents total revenues by geographic area based on the location products were shipped to and services provided (in thousands): Three Months Ended September 30, Nine Months Ended September 30, 2021 2020 2021 2020 United States $ 4,037 $ 2,288 $ 8,463 $ 6,349 Americas, excluding United States 147 85 675 194 Europe, Middle East and Africa 1,614 1,366 7,684 2,634 Asia and Pacific 1,957 2,208 4,904 3,351 Total $ 7,755 $ 5,947 $ 21,726 $ 12,528

Description of Business and B_2

Description of Business and Basis of Presentation (Details)	Mar. 11, 2021USD ($)$ / sharesshares	Dec. 21, 2020USD ($)$ / sharesshares	Sep. 30, 2021USD ($)$ / sharesshares	Mar. 10, 2021$ / shares	Dec. 31, 2020USD ($)$ / sharesshares
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Accumulated deficit | $			$ 275,012,000		$ 209,375,000
Schedule of Reverse Recapitalization [Line Items]
Common stock, shares outstanding (in shares)	161,449,205		161,529,449		33,327,294
Common stock, shares issued (in shares)			161,529,449		33,327,294
Common stock, par value (in dollars per share) | $ / shares	$ 0.0001	$ 0.0001	$ 0.0001		$ 0.0001
Warrants outstanding (in shares)	15,999,996
Preferred stock, par value (in dollars per share) | $ / shares			$ 0.0001		$ 0.0001
Common stock, deemed value (in dollars per share) | $ / shares	$ 10
Gross proceeds from merger and private offering | $	$ 299,900,000
Pre-merger cost | $	8,500,000
Offering cost | $	$ 26,600,000
Private Placement
Schedule of Reverse Recapitalization [Line Items]
Common stock, deemed value (in dollars per share) | $ / shares		$ 10
Sale of stock, number of shares issued in transaction (in shares)		10,000,000
Sale of stock, aggregate commitment amount | $		$ 100,000,000
Common Stock
Schedule of Reverse Recapitalization [Line Items]
Stock converted (in shares)	150,000,000
CLA | CLA Warrants
Schedule of Reverse Recapitalization [Line Items]
Warrants outstanding (in shares)		10,000,000
CLA | Private Placement Warrants
Schedule of Reverse Recapitalization [Line Items]
Warrants outstanding (in shares)		6,000,000
CLA | Conversion of Class B Common Stock to Class A Common Stock
Schedule of Reverse Recapitalization [Line Items]
Ordinary shares, conversion ratio		1
CLA | Conversion of Class A Common Stock to Common Stock
Schedule of Reverse Recapitalization [Line Items]
Ordinary shares, conversion ratio		1
CLA | Conversion of Warrant to Ouster Common Stock
Schedule of Reverse Recapitalization [Line Items]
Warrant, conversion ratio		1
CLA | Conversion of Canceled CLA Units to Ouster Common Stock
Schedule of Reverse Recapitalization [Line Items]
Unit, conversion ratio		1
CLA | Conversion of Canceled CLA Units to Public Warrant
Schedule of Reverse Recapitalization [Line Items]
Unit, conversion ratio		0.5
CLA | Common Class B
Schedule of Reverse Recapitalization [Line Items]
Common stock, shares outstanding (in shares)		5,000,000
Common stock, shares issued (in shares)		5,000,000
Common stock, par value (in dollars per share) | $ / shares		$ 0.0001
CLA | Common Class A
Schedule of Reverse Recapitalization [Line Items]
Common stock, shares outstanding (in shares)		25,000,000
Common stock, shares issued (in shares)		25,000,000
Common stock, par value (in dollars per share) | $ / shares		$ 0.0001
OTI
Schedule of Reverse Recapitalization [Line Items]
Common stock, par value (in dollars per share) | $ / shares				$ 0.00001
OTI | Series B Preferred Stock Converted to Common Stock
Schedule of Reverse Recapitalization [Line Items]
Preferred stock, conversion ratio				1
OTI | Series B Redeemable Convertible Preferred Stock
Schedule of Reverse Recapitalization [Line Items]
Preferred stock, par value (in dollars per share) | $ / shares				$ 0.00001

Summary of Significant Accoun_4

Summary of Significant Accounting Policies - Narrative (Details)	9 Months Ended	12 Months Ended
	Sep. 30, 2021	Dec. 31, 2020
Disaggregation of Revenue [Line Items]
Threshold period past due	90 days
Accounts Payable | Supplier Concentration Risk | Supplier A
Disaggregation of Revenue [Line Items]
Concentration risk, percentage	50.00%	23.00%

Summary of Significant Accoun_5

Summary of Significant Accounting Policies - Schedule of Concentration Risk (Details)	3 Months Ended		9 Months Ended		12 Months Ended
	Sep. 30, 2021	Sep. 30, 2020	Sep. 30, 2021	Sep. 30, 2020	Dec. 31, 2020
Total Purchase | Supplier Concentration Risk | Supplier A
Concentration Risk [Line Items]
Concentration risk, percentage (less than 10% for cells with asterisk)	19.00%	19.00%	17.00%	15.00%
Accounts Payable | Supplier Concentration Risk | Supplier A
Concentration Risk [Line Items]
Concentration risk, percentage (less than 10% for cells with asterisk)			50.00%		23.00%
Customer A | Accounts Receivable | Customer Concentration Risk
Concentration Risk [Line Items]
Concentration risk, percentage (less than 10% for cells with asterisk)			10.00%		13.00%
Customer B | Accounts Receivable | Customer Concentration Risk
Concentration Risk [Line Items]
Concentration risk, percentage (less than 10% for cells with asterisk)			10.00%		23.00%
Customer C | Accounts Receivable | Customer Concentration Risk
Concentration Risk [Line Items]
Concentration risk, percentage (less than 10% for cells with asterisk)			14.00%	10.00%
Customer D | Revenue | Customer Concentration Risk
Concentration Risk [Line Items]
Concentration risk, percentage (less than 10% for cells with asterisk)	10.00%	10.00%	10.00%	10.00%
Customer E | Revenue | Customer Concentration Risk
Concentration Risk [Line Items]
Concentration risk, percentage (less than 10% for cells with asterisk)	10.00%	10.00%	10.00%	16.00%

Fair Value of Financial Instr_3

Fair Value of Financial Instruments - Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis (Details) - Fair Value, Recurring - USD ($) $ in Thousands	Sep. 30, 2021	Dec. 31, 2020
Assets
Total financial assets	$ 219,276	$ 10,493
Liabilities
Warrant liabilities	10,979	49,293
Total financial liabilities	10,979	49,293
Level 1
Assets
Total financial assets	219,276	10,493
Liabilities
Warrant liabilities	0	0
Total financial liabilities	0	0
Level 2
Assets
Total financial assets	0	0
Liabilities
Warrant liabilities	0	0
Total financial liabilities	0	0
Level 3
Assets
Total financial assets	0	0
Liabilities
Warrant liabilities	10,979	49,293
Total financial liabilities	10,979	49,293
Money Market Funds
Assets
Money market funds	219,276	10,493
Money Market Funds | Level 1
Assets
Money market funds	219,276	10,493
Money Market Funds | Level 2
Assets
Money market funds	0	0
Money Market Funds | Level 3
Assets
Money market funds	$ 0	$ 0

Fair Value of Financial Instr_4

Fair Value of Financial Instruments - Schedule of Changes in the Fair Value of Level 3 Financial Instruments (Details) - Level 3 - USD ($) $ in Thousands	9 Months Ended
	Sep. 30, 2021	Sep. 30, 2020
Redeemable Convertible Preferred Stock Warrant Liability
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]
Fair value, beginning balance	$ (49,293)	$ (162)
Change in the fair value included in other income (expense), net	(8,804)	(6,097)
Recognition of preferred stock warrant and tranche liability upon issuance		(691)
Private placement warrant liability acquired as part of the Merger	0
Issuance of preferred stock upon exercise of warrants	58,097
Fair Value, ending balance	0	(6,950)
Redeemable Convertible Preferred Stock Tranche Liability
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]
Fair value, beginning balance		0
Recognition of preferred stock warrant and tranche liability upon issuance		(1,610)
Settlement of redeemable convertible preferred stock tranche liability due to the issuance of Series B redeemable convertible preferred stock		1,610
Fair Value, ending balance		0
Private Placement Warrant Liability
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]
Fair value, beginning balance	0	0
Change in the fair value included in other income (expense), net	8,398	0
Private placement warrant liability acquired as part of the Merger	(19,377)
Issuance of preferred stock upon exercise of warrants	0
Fair Value, ending balance	(10,979)	0
Derivative Liability
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]
Fair value, beginning balance	0	0
Change in the fair value included in other income (expense), net	0	(5,308)
Extinguishment of derivative liability upon conversion of convertible notes		5,308
Private placement warrant liability acquired as part of the Merger	0
Issuance of preferred stock upon exercise of warrants	0
Fair Value, ending balance	$ 0	$ 0

Balance Sheet Components - Sche

Balance Sheet Components - Schedule of Cash and Cash Equivalents (Details) - USD ($) $ in Thousands	Sep. 30, 2021	Dec. 31, 2020	Sep. 30, 2020
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Cash	$ 2,300	$ 869
Cash equivalents:
Money market funds	219,276	10,493
Total cash and cash equivalents	$ 221,576	$ 11,362	$ 18,367

Balance Sheet Components - Narr

Balance Sheet Components - Narrative (Details) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2021	Sep. 30, 2020	Sep. 30, 2021	Sep. 30, 2020	Dec. 31, 2020
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Restricted cash	$ 2,000		$ 2,000		$ 1,300
Restricted cash, current	1,008	$ 276	1,008	$ 276	276
Restricted cash, non-current	1,004	1,280	1,004	1,280	1,004
Inventory write down	2,600		2,600		$ 2,700
Inventory write down	$ 700	$ 0	$ 866	$ 1,156

Balance Sheet Components - Reco

Balance Sheet Components - Reconciliation of Cash, Cash Equivalents and Restricted Cash Reported (Details) - USD ($) $ in Thousands	Sep. 30, 2021	Dec. 31, 2020	Sep. 30, 2020	Dec. 31, 2019
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Cash and cash equivalents	$ 221,576	$ 11,362	$ 18,367
Restricted cash, current	1,008	276	276
Restricted cash, non-current	1,004	1,004	1,280
Total cash, cash equivalents and restricted cash	$ 223,588	$ 12,642	$ 19,923	$ 18,405

Balance Sheet Components - Sc_2

Balance Sheet Components - Schedule of Inventory (Details) - USD ($) $ in Thousands	Sep. 30, 2021	Dec. 31, 2020
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Raw materials	$ 2,269	$ 1,376
Work in process	2,165	1,249
Finished goods	2,068	2,192
Total inventory	$ 6,502	$ 4,817

Balance Sheet Components - Sc_3

Balance Sheet Components - Schedule of Prepaid Expenses and Other Current Assets (Details) - USD ($) $ in Thousands	Sep. 30, 2021	Dec. 31, 2020
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Prepaid insurance	$ 3,473	$ 206
Prepaid expenses	1,583	694
Receivable from contract manufacturer	53	1,521
Security deposit	1,179	20
Total prepaid and other current assets	$ 6,288	$ 2,441

Balance Sheet Components - Sc_4

Balance Sheet Components - Schedule of Accrued and Other Current Liabilities (Details) - USD ($) $ in Thousands	Sep. 30, 2021	Dec. 31, 2020
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Customer deposits	$ 48	$ 71
Accrued compensation	2,640	1,618
Uninvoiced receipts	7,726	1,947
Other	1,024	485
Accrued and other current liabilities	$ 11,438	$ 4,121

Debt - Narrative (Details)

Debt - Narrative (Details) $ / shares in Units, $ in Thousands	Mar. 26, 2021USD ($)	Aug. 05, 2019USD ($)shares	Nov. 27, 2018USD ($)$ / sharesshares	Jan. 31, 2021USD ($)	Sep. 30, 2021USD ($)	Sep. 30, 2021USD ($)	Sep. 30, 2020USD ($)	Dec. 31, 2020USD ($)
Debt Instrument [Line Items]
Warrants, loss (gain) from fair value adjustment						$ 406	$ 6,097
Runway Loan and Security Agreement | Secured Debt
Debt Instrument [Line Items]
Debt instrument, maximum borrowing capacity			$ 10,000
Effective interest rate					16.40%	16.40%	16.40%
Value of stock called by warrant, percentage of debt face amount			0.040
Debt instrument, face amount			$ 10,000
Fair value of warrant accounted for as debt discount			$ 100
Repayments of debt	$ 7,000
Payment of interest and fee upon extinguishment of debt	$ 400
Debt, outstanding balance					$ 0	$ 0		$ 7,000
Promissory Note | Notes Payable, Other Payables | Investor
Debt Instrument [Line Items]
Basis spread on variable rate				8.50%
Promissory notes, outstanding balance				$ 5,000
Series A Redeemable Convertible Preferred Stock Warrants
Debt Instrument [Line Items]
Warrants issued, number of preferred stock callable (in shares) | shares		53,023	35,348
Warrants issued, exercise price (in dollars per share) | $ / shares			$ 11.3518
Warrants, loss (gain) from fair value adjustment		$ 100
Series A Redeemable Convertible Preferred Stock Warrants | Other Income (Expense), Net
Debt Instrument [Line Items]
Warrants, loss (gain) from fair value adjustment					$ 600	$ 600	$ (200)
London Interbank Offered Rate (LIBOR) | Runway Loan and Security Agreement | Secured Debt
Debt Instrument [Line Items]
Basis spread on variable rate			8.50%
Prime Rate | LIBOR Rate Not Available or Applicable | Runway Loan and Security Agreement | Secured Debt
Debt Instrument [Line Items]
Basis spread on variable rate			6.00%
Applicable Interest Rate at the Time of Default | In the Event of Debt Default | Runway Loan and Security Agreement | Secured Debt
Debt Instrument [Line Items]
Basis spread on variable rate						5.00%

Warrants - Narrative (Details)

Warrants - Narrative (Details)	Aug. 05, 2019USD ($)$ / sharesshares	Aug. 31, 2020USD ($)$ / sharesshares	May 31, 2020$ / sharesshares	Sep. 30, 2021USD ($)	Sep. 30, 2021USD ($)	Sep. 30, 2020USD ($)	Mar. 11, 2021USD ($)shares	Dec. 31, 2020USD ($)	Dec. 21, 2020shares	Apr. 03, 2020USD ($)$ / sharesshares	Nov. 27, 2018USD ($)$ / sharesshares
Class of Warrant or Right [Line Items]
Warrant, fair value				$ 10,979,000	$ 10,979,000			$ 49,293,000
Warrants, loss (gain) from fair value adjustment					406,000	$ 6,097,000
Warrants outstanding (in shares) | shares							15,999,996
CLA | Conversion of Warrant to Ouster Common Stock
Class of Warrant or Right [Line Items]
Warrant, conversion ratio									1
OTI | Series B Redeemable Convertible Preferred Stock
Class of Warrant or Right [Line Items]
Issuance of redeemable convertible preferred stock (in shares) | shares			62,505,102
Preferred stock issued (in dollars per share) | $ / shares			$ 0.3323
Series A Redeemable Convertible Preferred Stock Warrants
Class of Warrant or Right [Line Items]
Warrants issued, number of preferred stock callable (in shares) | shares	53,023										35,348
Warrants issued, exercise price (in dollars per share) | $ / shares											$ 11.3518
Warrants, loss (gain) from fair value adjustment	$ 100,000
Series A Redeemable Convertible Preferred Stock Warrants | OTI
Class of Warrant or Right [Line Items]
Warrants issued, number of preferred stock callable (in shares) | shares	53,023										35,348
Warrants issued, exercise price (in dollars per share) | $ / shares	$ 11.3518										$ 11.3518
Warrant, fair value	$ 100,000										$ 100,000
Series A Redeemable Convertible Preferred Stock Warrants | Other Income (Expense), Net
Class of Warrant or Right [Line Items]
Warrants, loss (gain) from fair value adjustment				600,000	600,000	$ (200,000)
Series B Redeemable Convertible Preferred Stock Warrants | OTI
Class of Warrant or Right [Line Items]
Warrants issued, number of preferred stock callable (in shares) | shares										4,513,993
Warrants issued, exercise price (in dollars per share) | $ / shares										$ 0.3323
Warrant, fair value										$ 700,000
Series B Redeemable Convertible Preferred Stock Warrants | Other Income (Expense), Net | OTI
Class of Warrant or Right [Line Items]
Warrants, loss (gain) from fair value adjustment					8,300,000
Series B Redeemable Convertible Preferred Stock Warrants | Maximum | OTI
Class of Warrant or Right [Line Items]
Warrant, expiration period										10 years
Redeemable Convertible Preferred Stock Tranche Right | OTI
Class of Warrant or Right [Line Items]
Warrants issued, exercise price (in dollars per share) | $ / shares			$ 0.3323
Private Placement Warrants | Sponsor
Class of Warrant or Right [Line Items]
Warrants issued, number of preferred stock callable (in shares) | shares		6,000,000
Warrants issued, exercise price (in dollars per share) | $ / shares		$ 11.50
Warrant, fair value		$ 19,400,000
Warrant, expiration period		5 years
Sale of warrants, price (in dollars per share) | $ / shares		$ 1
Warrant, aggregated purchase price		$ 6,000,000
Warrant, exercisable, threshold period		12 months
Number of ordinary shares called by each warrant (in shares) | shares		1
Private Placement Warrants | Sponsor | Conversion of Warrant to Ouster Common Stock
Class of Warrant or Right [Line Items]
Warrant, conversion ratio							1
Private Placement Warrants | CLA
Class of Warrant or Right [Line Items]
Warrants outstanding (in shares) | shares									6,000,000
Private Placement Warrants | Other Income (Expense), Net | Sponsor
Class of Warrant or Right [Line Items]
Warrants, loss (gain) from fair value adjustment				$ 14,500,000	$ 8,400,000
Public Warrants
Class of Warrant or Right [Line Items]
Sale of warrants, price (in dollars per share) | $ / shares		$ 0.01
Exercise of warrant, threshold common stock price (in dollars per share) | $ / shares		$ 18
Exercise of warrant, threshold trading days		20 days
Exercise of warrant, threshold trading-day period		30 days
Public Warrants | CLA
Class of Warrant or Right [Line Items]
Warrants issued, number of preferred stock callable (in shares) | shares		20,000,000
Warrants issued, exercise price (in dollars per share) | $ / shares		$ 11.50
Warrant, fair value							$ 17,900,000
Warrant, expiration period		5 years
Warrant, exercisable, threshold period		12 months
Warrant, conversion ratio		1
Warrants outstanding (in shares) | shares							9,999,996

Warrants - Schedule of Fair Val

Warrants - Schedule of Fair Value Measurement Inputs of Redeemable Convertible Preferred Stock Warrants (Details) - Valuation Technique, Option Pricing Model - Redeemable Convertible Preferred Stock Warrants - OTI	Mar. 11, 2021$ / sharesyear	Feb. 11, 2021year$ / shares	Dec. 31, 2020$ / sharesyear	Apr. 03, 2020year$ / shares	Nov. 27, 2018year$ / shares
Stock price
Class of Warrant or Right [Line Items]
Warrants, fair value measurement inputs | $ / shares	8.44	10.27	7.11	5.80	5.80
Expected term (years)
Class of Warrant or Right [Line Items]
Warrants, fair value measurement inputs | year	2	2	2	9.31	10
Expected volatility
Class of Warrant or Right [Line Items]
Warrants, fair value measurement inputs	0.7600	0.7600	0.7600	0.5735	0.5781
Risk-free interest rate
Class of Warrant or Right [Line Items]
Warrants, fair value measurement inputs	0.0013	0.0013	0.0013	0.0175	0.0306
Dividend yield
Class of Warrant or Right [Line Items]
Warrants, fair value measurement inputs	0	0	0	0	0

Warrants - Schedule of Fair V_2

Warrants - Schedule of Fair Value Measurement Inputs of Private Placement Warrants (Details) - Valuation Technique, Option Pricing Model - Private Placement Warrants	Sep. 30, 2021$ / sharesyear	Jun. 30, 2021year$ / shares	Mar. 31, 2021$ / sharesyear	Mar. 11, 2021year$ / shares
Stock price
Class of Warrant or Right [Line Items]
Warrants, fair value measurement inputs | $ / shares	7.32	12.49	8.50	12
Exercise price of warrant
Class of Warrant or Right [Line Items]
Warrants, fair value measurement inputs	11.5	11.5	11.5	11.5
Expected term (years)
Class of Warrant or Right [Line Items]
Warrants, fair value measurement inputs	4.44	4.7	4.95	5
Expected volatility
Class of Warrant or Right [Line Items]
Warrants, fair value measurement inputs	0.4600	0.4300	0.4300	0.2700
Risk-free interest rate
Class of Warrant or Right [Line Items]
Warrants, fair value measurement inputs	0.0090	0.0092	0.0092	0.0078

Commitments and Contingencies (

Commitments and Contingencies (Details)	Sep. 30, 2021USD ($)	Dec. 31, 2020USD ($)	Sep. 30, 2017letter_of_credit
Commitments and Contingencies Disclosure [Abstract]
Number of letters of credit | letter_of_credit			2
Outstanding letter of credit	$ 1,300,000	$ 1,300,000
Third Party Contract Manufacturer
Loss Contingencies [Line Items]
Non-cancelable purchase commitments	6,400,000
Other Vendors
Loss Contingencies [Line Items]
Non-cancelable purchase commitments	10,500,000
Indemnification Agreement
Loss Contingencies [Line Items]
Potential obligations	$ 0	$ 0

Redeemable Convertible Prefer_3

Redeemable Convertible Preferred and Common Stock - Narrative (Details)		Mar. 10, 2021$ / sharesshares	Aug. 31, 2020USD ($)$ / sharesshares	Jul. 31, 2020USD ($)$ / shares	Jul. 30, 2020shares	May 31, 2020USD ($)$ / sharesshares	Apr. 30, 2020USD ($)$ / sharesshares	Dec. 31, 2017USD ($)$ / sharesshares	Oct. 31, 2017USD ($)$ / sharesshares	Jul. 31, 2016USD ($)$ / sharesshares	May 31, 2016USD ($)$ / sharesshares	Apr. 30, 2016USD ($)$ / sharesshares	Mar. 31, 2021shares	Sep. 30, 2020shares	Jun. 30, 2020shares	Sep. 30, 2020USD ($)	Sep. 30, 2021$ / sharesshares	Mar. 11, 2021vote$ / sharesshares	Dec. 31, 2020$ / sharesshares	Dec. 21, 2020$ / shares
Class of Stock [Line Items]
Common stock, par value (in dollars per share) | $ / shares																	$ 0.0001	$ 0.0001	$ 0.0001	$ 0.0001
Preferred stock, par value (in dollars per share) | $ / shares																	$ 0.0001		$ 0.0001
Common stock, shares authorized (in shares) | shares																	1,000,000,000		210,956,516
Preferred stock, shares authorized (in shares) | shares																	100,000,000		0
Common stock, shares outstanding (in shares) | shares																	161,529,449	161,449,205	33,327,294
Warrants outstanding (in shares) | shares																		15,999,996
Common stock, voting rights, number of votes per share | vote																		1
Redeemable convertible preferred stock, shares authorized (in shares) | shares																	0		131,411,372
Redeemable convertible preferred stock, issue price (in dollars per share) | $ / shares																		$ 10
Payment of offering costs | $																$ 265,000
OTI
Class of Stock [Line Items]
Common stock, par value (in dollars per share) | $ / shares		$ 0.00001
Common stock, shares authorized (in shares) | shares		210,956,516
Stock, shares authorized (in shares) | shares		342,367,887
Authorized stock, par value (in dollars per share) | $ / shares		$ 0.00001
Stock issued from conversion of note (in shares) | shares									1,253,556
Convertible notes payable | $									$ 4,600,000
Investor | OTI
Class of Stock [Line Items]
Stock issued from conversion of note (in shares) | shares												44,256
Convertible notes payable | $												$ 45,000
Redeemable convertible preferred stock
Class of Stock [Line Items]
Redeemable convertible preferred stock, shares issued (in shares) | shares	[1]												4,232,947	44,481,892	43,952,862
Redeemable convertible preferred stock | OTI
Class of Stock [Line Items]
Redeemable convertible preferred stock, shares authorized (in shares) | shares		131,411,372
Series Seed Redeemable Convertible Preferred Stock | OTI
Class of Stock [Line Items]
Redeemable convertible preferred stock, shares issued (in shares) | shares										445,942	563,725	1,887,253
Redeemable convertible preferred stock, issue price (in dollars per share) | $ / shares										$ 1.02	$ 1.02	$ 1.02
Proceeds from issuance of redeemable convertible preferred stock, net off issuance cost | $										$ 500,000	$ 600,000	$ 1,800,000
Payment of offering costs | $												$ 100,000
Stock issued during period, conversion of convertible securities (in shares) | shares							2,941,176
Redeemable convertible preferred stock dividends (in dollars per share) | $ / shares		$ 0.0612
Liquidation preference (in dollars per share) | $ / shares		1.02
Convertible preferred stock, conversion price (in dollars per share) | $ / shares		1.02
Series A Redeemable Convertible Preferred Stock | OTI
Class of Stock [Line Items]
Redeemable convertible preferred stock, shares issued (in shares) | shares								715,712	1,324,511
Redeemable convertible preferred stock, issue price (in dollars per share) | $ / shares								$ 11.3158	$ 11.3158
Proceeds from issuance of redeemable convertible preferred stock, net off issuance cost | $								$ 8,100,000	$ 14,800,000
Payment of offering costs | $									$ 200,000
Stock issued during period, conversion of convertible securities (in shares) | shares							3,293,779
Redeemable convertible preferred stock dividends (in dollars per share) | $ / shares		0.6789
Liquidation preference (in dollars per share) | $ / shares		11.3518
Convertible preferred stock, conversion price (in dollars per share) | $ / shares		11.3518
Series B | OTI
Class of Stock [Line Items]
Redeemable convertible preferred stock, shares authorized (in shares) | shares																			131,411,372
Redeemable convertible preferred stock, shares issued (in shares) | shares			25,286,587		37,970,846	17,320,031	45,185,071
Redeemable convertible preferred stock, issue price (in dollars per share) | $ / shares			$ 0.3323	$ 0.3323		$ 0.3323	$ 0.3323												$ 0.33
Proceeds from issuance of redeemable convertible preferred stock, net off issuance cost | $			$ 8,400,000	$ 12,500,000		$ 5,800,000	$ 15,100,000
Payment of offering costs | $			$ 100,000	$ 100,000		$ 100,000	$ 100,000
Redeemable convertible preferred stock dividends (in dollars per share) | $ / shares		0.019938
Liquidation preference (in dollars per share) | $ / shares		0.3323
Convertible preferred stock, conversion price (in dollars per share) | $ / shares		$ 0.3323
[1]	The shares of the Company’s common and redeemable convertible preferred stock, prior to the Merger (as defined in Note 1), have been retroactively restated as shares reflecting the exchange ratio of approximately 0.703 established in the Merger as described in Note 1.

Redeemable Convertible Prefer_4

Redeemable Convertible Preferred and Common Stock - Schedule of Redeemable Convertible Preferred Stock (Details) - USD ($) $ / shares in Units, $ in Thousands	Sep. 30, 2021	Mar. 11, 2021	Dec. 31, 2020	Aug. 31, 2020	Jul. 31, 2020	May 31, 2020	Apr. 30, 2020
Class of Stock [Line Items]
Issue Price per share		$ 10
Shares Authorized (in shares)	0		131,411,372
Shares Issued (in shares)	0		88,434,754
Shares Outstanding (in shares)	0		88,434,754
Liquidation Amount	$ 0		$ 41,791
Carrying Amount	$ 0		$ 39,225
Series B | OTI
Class of Stock [Line Items]
Issue Price per share			$ 0.33	$ 0.3323	$ 0.3323	$ 0.3323	$ 0.3323
Shares Authorized (in shares)			131,411,372
Shares Issued (in shares)			88,434,754
Shares Outstanding (in shares)			88,434,754
Liquidation Amount			$ 41,791
Carrying Amount			$ 39,225

Stock-based compensation - Narr

Stock-based compensation - Narrative (Details) - USD ($) $ / shares in Units, $ in Thousands	Mar. 11, 2021	Oct. 12, 2020	Mar. 31, 2021	Mar. 31, 2021	Sep. 30, 2021	Sep. 30, 2020	Dec. 31, 2020
Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]
Options, grants in period (in shares)					645,796
Management And Employee
Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]
Promissory notes, percentage forgiven			50.00%
Certain Executives
Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]
Proceeds from noteholders debt			$ 300
Non-executive Noteholders
Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]
Partial recourse promissory notes					$ 500
2015 Stock Plan | Management And Employee | OTI
Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]
Partial recourse promissory notes		$ 1,100
Stated interest rate		0.38%
Vested options, exercised in period (in shares)		2,883,672
Unvested options, exercised in period (in shares)		4,603,833
2015 Stock Plan | Certain Executives
Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]
Compensation cost upon forgiveness of promissory notes				$ 300	$ 300
2021 Incentive Award Plan
Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]
Number of shares reserved for issuance (in shares)	18,558,576				13,680,487
Increase in number of shares authorized, annual increase percentage	5.00%
Number of common stock received upon vesting of each performance stock unit (in shares)	1
Options, weighted average grant date fair value (in dollars per share)					$ 5.9
Unamortized stock-based compensation expense of option					$ 27,500
Option | 2021 Incentive Award Plan
Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]
Option expiration period (up to)	10 years
Unamortized stock-based compensation expense, period for recognition					1 year 8 months 12 days
Option | 2021 Incentive Award Plan | Employee
Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]
Minimum exercise price as percentage of fair value of shares on grant date	100.00%
Option | 2021 Incentive Award Plan | A Shareholder With 10% Ownership
Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]
Option expiration period (up to)	5 years
Minimum exercise price as percentage of fair value of shares on grant date	110.00%
Shareholder ownership percentage	10.00%
Option | 2021 Incentive Award Plan | One Senior Advisor
Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]
Options, grants in period (in shares)	1,614,492
Award vesting period	5 years
Threshold percentage of exercise price	130.00%
Threshold consecutive trading days	30 days
Number of shares forfeited (in shares)							1,614,492
Stock Appreciation Rights | 2021 Incentive Award Plan
Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]
Option expiration period (up to)	10 years
Restricted Stock
Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]
Stock granted in period, other than options (in shares)					0
RSAs granted in period (in shares)					$ 0
Restricted Stock | 2021 Incentive Award Plan
Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]
RSAs granted in period (in shares)					$ 0
RSAs vested in period, fair value					$ 100
Restricted Stock | 2021 Incentive Award Plan | Employee
Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]
Award vesting period	4 years
Award vesting rights, vested percentage	100.00%
Restricted Stock Units (RSUs)
Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]
Stock granted in period, other than options (in shares)					4,332,224
RSAs granted in period (in shares)					$ 9.50
Restricted Stock Units (RSUs) | 2021 Incentive Award Plan
Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]
Unamortized stock-based compensation expense, period for recognition						3 years 2 months 12 days
Unrecognized stock-based compensation expense						$ 34,200
Restricted Stock Units (RSUs) | 2021 Incentive Award Plan | Employee
Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]
Award vesting period	4 years
Award vesting rights, vested percentage	100.00%
Restricted Stock Units (RSUs) | 2021 Incentive Award Plan | One Senior Advisor
Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]
Award vesting period	5 years
Stock granted in period, other than options (in shares)	807,246
Restricted Stock Units (RSUs) | 2021 Incentive Award Plan | Several Members of the Board of Directors
Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]
Stock granted in period, other than options (in shares)			152,628
Performance Stock Unit | 2021 Incentive Award Plan | One Senior Advisor
Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]
Award vesting period	4 years
Stock granted in period, other than options (in shares)	807,246
Percentage of performance stock units	25.00%
Performance Stock Unit | 2021 Incentive Award Plan | Minimum | One Senior Advisor
Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]
Performance stock, stock price increase percentage	150.00%
Performance Stock Unit | 2021 Incentive Award Plan | Maximum | One Senior Advisor
Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]
Performance stock, stock price increase percentage	300.00%
Share-based Payment Arrangement, Tranche One | Option | 2021 Incentive Award Plan | One Senior Advisor
Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]
Award vesting schedule in percentage	20.00%
Share-based Payment Arrangement, Tranche One | Restricted Stock | 2021 Incentive Award Plan | Employee
Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]
Award vesting schedule in percentage	25.00%
Share-based Payment Arrangement, Tranche One | Restricted Stock Units (RSUs) | 2021 Incentive Award Plan | Employee
Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]
Award vesting schedule in percentage	25.00%
Share-based Payment Arrangement, Tranche One | Restricted Stock Units (RSUs) | 2021 Incentive Award Plan | One Senior Advisor
Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]
Award vesting schedule in percentage	20.00%
Share-based Payment Arrangement, Tranche Two | Option | 2021 Incentive Award Plan | One Senior Advisor
Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]
Award vesting schedule in percentage	20.00%
Share-based Payment Arrangement, Tranche Two | Restricted Stock | 2021 Incentive Award Plan | Employee
Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]
Award vesting schedule in percentage	25.00%
Share-based Payment Arrangement, Tranche Two | Restricted Stock Units (RSUs) | 2021 Incentive Award Plan | Employee
Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]
Award vesting schedule in percentage	25.00%
Share-based Payment Arrangement, Tranche Two | Restricted Stock Units (RSUs) | 2021 Incentive Award Plan | One Senior Advisor
Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]
Award vesting schedule in percentage	20.00%
Share-based Payment Arrangement, Tranche Three | Option | 2021 Incentive Award Plan | One Senior Advisor
Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]
Award vesting schedule in percentage	20.00%
Share-based Payment Arrangement, Tranche Three | Restricted Stock | 2021 Incentive Award Plan | Employee
Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]
Award vesting schedule in percentage	25.00%
Share-based Payment Arrangement, Tranche Three | Restricted Stock Units (RSUs) | 2021 Incentive Award Plan | Employee
Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]
Award vesting schedule in percentage	25.00%
Share-based Payment Arrangement, Tranche Three | Restricted Stock Units (RSUs) | 2021 Incentive Award Plan | One Senior Advisor
Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]
Award vesting schedule in percentage	20.00%
Share-based Payment Arrangement, Tranche Four | Option | 2021 Incentive Award Plan | One Senior Advisor
Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]
Award vesting schedule in percentage	20.00%
Share-based Payment Arrangement, Tranche Four | Restricted Stock | 2021 Incentive Award Plan | Employee
Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]
Award vesting schedule in percentage	25.00%
Share-based Payment Arrangement, Tranche Four | Restricted Stock Units (RSUs) | 2021 Incentive Award Plan | Employee
Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]
Award vesting schedule in percentage	25.00%
Share-based Payment Arrangement, Tranche Four | Restricted Stock Units (RSUs) | 2021 Incentive Award Plan | One Senior Advisor
Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]
Award vesting schedule in percentage	20.00%
Share-based Payment Arrangement, Tranche Five | Option | 2021 Incentive Award Plan | One Senior Advisor
Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]
Award vesting schedule in percentage	20.00%
Share-based Payment Arrangement, Tranche Five | Restricted Stock Units (RSUs) | 2021 Incentive Award Plan | One Senior Advisor
Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]
Award vesting schedule in percentage	20.00%

Stock-based compensation - Sche

Stock-based compensation - Schedule of Stock Option Activity (Details) - USD ($) $ / shares in Units, $ in Thousands	3 Months Ended		9 Months Ended	12 Months Ended
	Mar. 31, 2020	[1]	Sep. 30, 2021	Dec. 31, 2020
Number of Shares Underlying Outstanding Options
Number of shares underlying outstanding options, beginning balance (in shares)			25,732,503
Number of shares underlying outstanding options, options granted (in shares)			645,796
Number of shares underlying outstanding options, options exercised (in shares)	(423)		(913,279)
Number of shares underlying outstanding options, options cancelled (in shares)			(505,213)
Number of shares underlying outstanding options, ending balance (in shares)			24,959,807	25,732,503
Number of shares underlying outstanding options, vested and expected to vest (in shares)			24,959,807
Number of shares underlying outstanding options, exercisable (in shares)			8,844,727
Weighted- Average Exercise Price per Share
Weighted average exercise price, beginning balance (in dollars per share)			$ 0.39
Weighted average exercise price, options granted (in dollars per share)			10.26
Weighted average exercise price, options exercised (in dollars per share)			0.14
Weighted average exercise price, options cancelled (in dollars per share)			0.14
Weighted average exercise price, ending balance (in dollars per share)			0.67	$ 0.39
Weighted average exercise price, options vested and expected to vest (in dollars per share)			0.67
Weighted average exercise price, options exercisable (in dollars per share)			$ 0.31
Weighted- Average Remaining Contractual Term (in years)
Stock options outstanding, weighted average remaining contractual term			8 years 8 months 12 days	9 years 7 months 6 days
Stock options granted, weighted average remaining contractual term
Stock options exercised, weighted average remaining contractual term
Stock options vested and expected to vest, weighted average remaining contractual term			8 years 8 months 12 days
Stock options exercisable, weighted average remaining contractual term			8 years 1 month 6 days
Aggregate Intrinsic Value
Stock options outstanding, aggregate intrinsic value, beginning balance			$ 245,746
Stock options granted, aggregate intrinsic value
Stock options exercised, aggregate intrinsic value
Stock options outstanding, aggregate intrinsic value, ending balance			167,460	$ 245,746
Stock options vested and expected to vest, aggregate intrinsic value			167,460
Stock options exercisable, aggregate intrinsic value			$ 61,987
[1]	The shares of the Company’s common and redeemable convertible preferred stock, prior to the Merger (as defined in Note 1), have been retroactively restated as shares reflecting the exchange ratio of approximately 0.703 established in the Merger as described in Note 1.

Stock-based compensation - Sc_2

Stock-based compensation - Schedule of Stock Options Valuation Assumptions (Details) - Option	9 Months Ended
	Sep. 30, 2021
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Expected term (years)	6 years
Expected volatility	63.19%
Risk-free interest rate	1.03%
Expected dividend rate	0.00%

Stock-based compensation - Sc_3

Stock-based compensation - Schedule of Stock Options Outstanding and Exercisable (Details)	9 Months Ended
	Sep. 30, 2021$ / sharesshares
Share-based Payment Arrangement, Option, Exercise Price Range [Line Items]
Options outstanding (in shares) | shares	24,959,807
Options exercisable (in shares) | shares	8,844,727
Exercise Price at $0.13
Share-based Payment Arrangement, Option, Exercise Price Range [Line Items]
Exercise price, lower range limit (in dollars per share)	$ 0.18
Exercise price, upper range limit (in dollars per share)	$ 0.18
Options outstanding (in shares) | shares	6,350,481
Options outstanding, weighted average remaining contractual life (years)	8 years 3 months 18 days
Options outstanding, weighted average exercise price (in dollars per share)	$ 0.18
Options exercisable (in shares) | shares	3,889,338
Options exercisable, weighted average remaining contractual life (years)	7 years 9 months 18 days
Options exercisable, weighted average exercise price (in dollars per share)	$ 0.18
Exercise Price at $0.15
Share-based Payment Arrangement, Option, Exercise Price Range [Line Items]
Exercise price, lower range limit (in dollars per share)	0.21
Exercise price, upper range limit (in dollars per share)	$ 0.21
Options outstanding (in shares) | shares	10,394,961
Options outstanding, weighted average remaining contractual life (years)	8 years 9 months 18 days
Options outstanding, weighted average exercise price (in dollars per share)	$ 0.21
Options exercisable (in shares) | shares	3,186,660
Options exercisable, weighted average remaining contractual life (years)	8 years 2 months 12 days
Options exercisable, weighted average exercise price (in dollars per share)	$ 0.21
Exercise Price at $0.26
Share-based Payment Arrangement, Option, Exercise Price Range [Line Items]
Exercise price, lower range limit (in dollars per share)	0.37
Exercise price, upper range limit (in dollars per share)	$ 0.37
Options outstanding (in shares) | shares	35,159
Options outstanding, weighted average remaining contractual life (years)	4 months 24 days
Options outstanding, weighted average exercise price (in dollars per share)	$ 0.37
Options exercisable (in shares) | shares	35,159
Options exercisable, weighted average remaining contractual life (years)	4 months 24 days
Options exercisable, weighted average exercise price (in dollars per share)	$ 0.37
Exercise Price at $1.00
Share-based Payment Arrangement, Option, Exercise Price Range [Line Items]
Exercise price, lower range limit (in dollars per share)	1.42
Exercise price, upper range limit (in dollars per share)	$ 1.42
Options outstanding (in shares) | shares	7,524,116
Options outstanding, weighted average remaining contractual life (years)	9 years
Options outstanding, weighted average exercise price (in dollars per share)	$ 1.42
Options exercisable (in shares) | shares	1,724,276
Options exercisable, weighted average remaining contractual life (years)	9 years
Options exercisable, weighted average exercise price (in dollars per share)	$ 1.42
Exercise Price at $3.92
Share-based Payment Arrangement, Option, Exercise Price Range [Line Items]
Exercise price, lower range limit (in dollars per share)	5.57
Exercise price, upper range limit (in dollars per share)	$ 5.57
Options outstanding (in shares) | shares	7,976
Options outstanding, weighted average remaining contractual life (years)	2 months 12 days
Options outstanding, weighted average exercise price (in dollars per share)	$ 5.57
Options exercisable (in shares) | shares	7,976
Options exercisable, weighted average remaining contractual life (years)	2 months 12 days
Options exercisable, weighted average exercise price (in dollars per share)	$ 5.57
Exercise Price at $5.80
Share-based Payment Arrangement, Option, Exercise Price Range [Line Items]
Exercise price, lower range limit (in dollars per share)	8.25
Exercise price, upper range limit (in dollars per share)	$ 8.25
Options outstanding (in shares) | shares	1,318
Options outstanding, weighted average remaining contractual life (years)	2 months 12 days
Options outstanding, weighted average exercise price (in dollars per share)	$ 8.25
Options exercisable (in shares) | shares	1,318
Options exercisable, weighted average remaining contractual life (years)	2 months 12 days
Options exercisable, weighted average exercise price (in dollars per share)	$ 8.25
Exercise Price at $10.26
Share-based Payment Arrangement, Option, Exercise Price Range [Line Items]
Exercise price, lower range limit (in dollars per share)	10.26
Exercise price, upper range limit (in dollars per share)	$ 10.26
Options outstanding (in shares) | shares	645,796
Options outstanding, weighted average remaining contractual life (years)	9 years 6 months
Options outstanding, weighted average exercise price (in dollars per share)	$ 10.26
Options exercisable (in shares) | shares	0
Options exercisable, weighted average exercise price (in dollars per share)	$ 0

Stock-based compensation - Sc_4

Stock-based compensation - Schedule of Nonvested Restricted Stock Awards Activity (Details) - Restricted Stock	9 Months Ended
	Sep. 30, 2021$ / sharesshares
Outstanding shares
Restricted stock awards, beginning balance (in shares) | shares	40,754
Granted (in shares) | shares	0
Canceled (in shares) | shares	0
Vested (in shares) | shares	(17,466)
Restricted stock awards, ending balance (in shares) | shares	23,288
Weighted Average Grant Date Fair Value
Beginning balance (in dollars per share) | $ / shares	$ 0.67
Granted (in dollars per share) | $ / shares	0
Canceled (in dollars per share) | $ / shares	0
Vested (in dollars per share) | $ / shares	0.67
Ending balance (in dollars per share) | $ / shares	$ 0.67

Stock-based compensation - Sc_5

Stock-based compensation - Schedule of Restricted Stock Units Activity (Details) - Restricted Stock Units (RSUs)	9 Months Ended
	Sep. 30, 2021$ / sharesshares
Outstanding shares
Restricted stock awards, beginning balance (in shares) | shares	0
Granted (in shares) | shares	4,332,224
Canceled (in shares) | shares	(27,636)
Vested (in shares) | shares	(463,043)
Restricted stock awards, ending balance (in shares) | shares	3,841,545
Weighted Average Grant Date Fair Value
Beginning balance (in dollars per share) | $ / shares	$ 0
Granted (in dollars per share) | $ / shares	9.50
Canceled (in dollars per share) | $ / shares	8.86
Vested (in dollars per share) | $ / shares	10.46
Ending balance (in dollars per share) | $ / shares	$ 9.21

Stock-based compensation - Sc_6

Stock-based compensation - Schedule of Stock-based Compensation (Details) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2021	Sep. 30, 2020	Sep. 30, 2021	Sep. 30, 2020
Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]
Total stock-based compensation	$ 7,147	$ 7,256	$ 18,557	$ 7,891
Cost of revenue
Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]
Total stock-based compensation	206	505	457	606
Research and development
Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]
Total stock-based compensation	2,063	4,889	4,305	5,177
Sales and marketing
Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]
Total stock-based compensation	1,717	319	2,702	408
General and administrative
Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]
Total stock-based compensation	$ 3,161	$ 1,543	$ 11,093	$ 1,700

Net Loss Per Common Share - Sch

Net Loss Per Common Share - Schedule of Net Loss Per Common Share, Basic and Diluted (Details) - USD ($) $ / shares in Units, $ in Thousands	3 Months Ended						9 Months Ended
	Sep. 30, 2021	Jun. 30, 2021	Mar. 31, 2021	Sep. 30, 2020	Jun. 30, 2020	Mar. 31, 2020	Sep. 30, 2021	Sep. 30, 2020
Numerator:
Net loss	$ (12,669)	$ (32,011)	$ (20,957)	$ (19,615)	$ (11,312)	$ (18,693)	$ (65,637)	$ (49,620)
Denominator [Abstract]
Weighted-average shares used to compute basic net loss per share (in shares)	156,647,259			20,303,631			123,175,390	15,753,057
Weighted-average shares used to compute diluted net loss per share (in shares)	156,647,259			20,303,631			123,175,390	15,753,057
Net loss per common share, basic (in dollars per share)	$ (0.08)			$ (0.97)			$ (0.53)	$ (3.15)
Net loss per common share, diluted (in dollars per share)	$ (0.08)			$ (0.97)			$ (0.53)	$ (3.15)

Net Loss Per Common Share - Nar

Net Loss Per Common Share - Narrative (Details)	Sep. 30, 2021	Sep. 30, 2020
Earnings Per Share [Abstract]
Share exchange ratio	0.703	0.703

Net Loss Per Common Share - S_2

Net Loss Per Common Share - Schedule of Antidilutive Securities Excluded from Computation of Net Loss Per Common Share (Details) - shares	9 Months Ended
	Sep. 30, 2021	Sep. 30, 2020
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive securities excluded from computation of net loss per share (in shares)	49,694,372	115,845,847
Redeemable convertible preferred stock
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive securities excluded from computation of net loss per share (in shares)	0	88,434,754
Options to purchase common stock
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive securities excluded from computation of net loss per share (in shares)	24,959,807	22,699,012
Unvested RSA
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive securities excluded from computation of net loss per share (in shares)	23,288	237,798
Restricted stock units
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive securities excluded from computation of net loss per share (in shares)	4,304,588	0
Unvested early exercised common stock options
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive securities excluded from computation of net loss per share (in shares)	2,234,455	30,421
Vested and early exercised options subject to nonrecourse notes
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive securities excluded from computation of net loss per share (in shares)	2,172,238	0
Preferred stock warrants
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive securities excluded from computation of net loss per share (in shares)	0	4,443,862
Public and private common stock warrants
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive securities excluded from computation of net loss per share (in shares)	15,999,996	0

Revenue - Narrative (Details)

Revenue - Narrative (Details) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2021	Sep. 30, 2020	Sep. 30, 2021	Sep. 30, 2020
Disaggregation of Revenue [Line Items]
Revenue	$ 7,755	$ 5,947	$ 21,726	$ 12,528
Product
Disaggregation of Revenue [Line Items]
Revenue	7,755	5,934	21,726	10,524
Product | Transferred at Point in Time
Disaggregation of Revenue [Line Items]
Revenue	$ 7,800	$ 5,900	$ 21,700	$ 10,500

Revenue - Schedule of Disaggreg

Revenue - Schedule of Disaggregation of Revenue (Details) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2021	Sep. 30, 2020	Sep. 30, 2021	Sep. 30, 2020
Disaggregation of Revenue [Line Items]
Revenue	$ 7,755	$ 5,947	$ 21,726	$ 12,528
United States
Disaggregation of Revenue [Line Items]
Revenue	4,037	2,288	8,463	6,349
Americas, excluding United States
Disaggregation of Revenue [Line Items]
Revenue	147	85	675	194
Europe, Middle East and Africa
Disaggregation of Revenue [Line Items]
Revenue	1,614	1,366	7,684	2,634
Asia and Pacific
Disaggregation of Revenue [Line Items]
Revenue	$ 1,957	$ 2,208	$ 4,904	$ 3,351

Subsequent Event (Details)

Subsequent Event (Details) - Sense Photonics, Inc. - Subsequent Event $ / shares in Units, shares in Millions, $ in Millions	Oct. 22, 2021USD ($)$ / sharesshares
Subsequent Event [Line Items]
Business acquisition, percentage of interests acquired	100.00%
Common Stock
Subsequent Event [Line Items]
Business acquisition, number of shares issued (in shares)	10
Business acquisition, share price (in dollars per share) | $ / shares	$ 6.55
Business combination, value of common shares issued | $	$ 63
Assumed Options
Subsequent Event [Line Items]
Business acquisition, number of shares issued (in shares)	0.8